PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

Assignment ID: PATI283790

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
NanoString Technologies, Inc.	05/03/2024

RECEIVING PARTY DATA

Company Name:	Bruker Spatial Biology, Inc.
Street Address:	c/o Bruker Corporation
Internal Address:	40 Manning Road
City:	Billerica
State/Country:	MASSACHUSETTS
Postal Code:	01821

PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	16596596

CORRESPONDENCE DATA

Fax Number: 2028427899

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 6179372300
Email: fvandermaelen@cooley.com
Correspondent Name: COOLEY LLP
Address Line 1: ATTN: IP Docketing Department
Address Line 2: 1299 Pennsylvania Avenue NW, Suite 700
Address Line 4: Washington, DISTRICT OF COLUMBIA 20004

ATTORNEY DOCKET NUMBER:	NATE-030C01US 321329-2549
NAME OF SUBMITTER:	Francesca Vandermaelen
SIGNATURE:	Francesca Vandermaelen
DATE SIGNED:	06/07/2024

Total Attachments: 49
source=NanoString to Bruker - Executed Assignment#page1.tif
source=NanoString to Bruker - Executed Assignment#page2.tif
source=NanoString to Bruker - Executed Assignment#page3.tif
source=NanoString to Bruker - Executed Assignment#page4.tif

source=NanoString to Bruker - Executed Assignment#page5.tif
source=NanoString to Bruker - Executed Assignment#page6.tif
source=NanoString to Bruker - Executed Assignment#page7.tif
source=NanoString to Bruker - Executed Assignment#page8.tif
source=NanoString to Bruker - Executed Assignment#page9.tif
source=NanoString to Bruker - Executed Assignment#page10.tif
source=NanoString to Bruker - Executed Assignment#page11.tif
source=NanoString to Bruker - Executed Assignment#page12.tif
source=NanoString to Bruker - Executed Assignment#page13.tif
source=NanoString to Bruker - Executed Assignment#page14.tif
source=NanoString to Bruker - Executed Assignment#page15.tif
source=NanoString to Bruker - Executed Assignment#page16.tif
source=NanoString to Bruker - Executed Assignment#page17.tif
source=NanoString to Bruker - Executed Assignment#page18.tif
source=NanoString to Bruker - Executed Assignment#page19.tif
source=NanoString to Bruker - Executed Assignment#page20.tif
source=NanoString to Bruker - Executed Assignment#page21.tif
source=NanoString to Bruker - Executed Assignment#page22.tif
source=NanoString to Bruker - Executed Assignment#page23.tif
source=NanoString to Bruker - Executed Assignment#page24.tif
source=NanoString to Bruker - Executed Assignment#page25.tif
source=NanoString to Bruker - Executed Assignment#page26.tif
source=NanoString to Bruker - Executed Assignment#page27.tif
source=NanoString to Bruker - Executed Assignment#page28.tif
source=NanoString to Bruker - Executed Assignment#page29.tif
source=NanoString to Bruker - Executed Assignment#page30.tif
source=NanoString to Bruker - Executed Assignment#page31.tif
source=NanoString to Bruker - Executed Assignment#page32.tif
source=NanoString to Bruker - Executed Assignment#page33.tif
source=NanoString to Bruker - Executed Assignment#page34.tif
source=NanoString to Bruker - Executed Assignment#page35.tif
source=NanoString to Bruker - Executed Assignment#page36.tif
source=NanoString to Bruker - Executed Assignment#page37.tif
source=NanoString to Bruker - Executed Assignment#page38.tif
source=NanoString to Bruker - Executed Assignment#page39.tif
source=NanoString to Bruker - Executed Assignment#page40.tif
source=NanoString to Bruker - Executed Assignment#page41.tif
source=NanoString to Bruker - Executed Assignment#page42.tif
source=NanoString to Bruker - Executed Assignment#page43.tif
source=NanoString to Bruker - Executed Assignment#page44.tif
source=NanoString to Bruker - Executed Assignment#page45.tif
source=NanoString to Bruker - Executed Assignment#page46.tif
source=NanoString to Bruker - Executed Assignment#page47.tif
source=NanoString to Bruker - Executed Assignment#page48.tif
source=NanoString to Bruker - Executed Assignment#page49.tif

PATENT ASSIGNMENT AGREEMENT

This Patent Assignment Agreement ("Patent Assignment Agreement") is made and entered into as of May 6, 2024 by and between Bruker Spatial Biology, Inc., a Delaware corporation (the "Assignee"), and NanoString Technologies, Inc., a Delaware corporation located at 530 Fairview Avenue North, Seattle, Washington 98109, (the "Assignor") (Assignee and Assignor are collectively referred to as the "Parties").

WHEREAS, Assignor is the owner, or a co-owner, of all right, title, and interest in and to all patents and patent applications set forth on Schedule A attached hereto, including all inventions described and claimed in the patents and patent applications (including divisionals, continuations-in-part, provisionals, reissues, reexaminations or interferences thereof) (the "Patents").

WHEREAS, pursuant to that certain Asset Purchase Agreement, dated as of April 17, 2024 by and between Bruker Corporation ("Bruker") and Assignor (the "Purchase Agreement"), Assignor agreed to assign, sell, convey, and transfer, and desires to assign, sell, convey, and transfer all of Assignor's right, title, and interest in and to the Patents to Bruker or its permitted designee(s), and Assignee, as a permitted designee of Bruker, desires to receive all right, title, and interest in and to the Patents.

NOW, THEREFORE, for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows:

1. Definitions. Capitalized terms used in this Patent Assignment Agreement that are not defined in the body of this Patent Assignment Agreement have the meanings given to them in the Purchase Agreement.

2. Assignment. Assignor does hereby irrevocably sell, convey, transfer, assign, and deliver to Assignee, its successors and assigns, and Assignee purchases and accepts from Assignor, all of Assignor's right, title, and interest in and to the Patents, including all rights to sue and receive all rights to and claims for all remedies for past, present, and future infringement, misappropriation or other violation thereof. Assignor further consents to recordation of this Patent Assignment Agreement by Assignee solely, including with the United States Patent and Trademark Office, similar foreign offices or successor offices.

3. Further Assurances. Assignor agrees to execute, at any time and from time to time upon the request and expense of Assignee, such additional documents as Assignee reasonably requests to register and otherwise give full effect to the rights of Assignee under this Patent Assignment Agreement in and to the Patents, including all documents necessary to record in the name of Assignee the assignment of the Patents with the United States Patent and Trademark Office or any national Patent and Trademark Office or their respective successor offices.

4. Governing Law. This Patent Assignment Agreement shall be construed in accordance with the domestic Laws of the State of New York, without giving effect to any choice of law or conflict of law provision or rule (whether of the State of New York or any other jurisdiction) that would cause the application of any jurisdiction other than the State of New York.

5. No Conflict. Nothing in this Patent Assignment Agreement shall alter any liability or obligation of the parties hereto arising under the Purchase Agreement. In the event of a conflict between the terms and conditions of this Agreement and the terms and conditions of the Purchase Agreement, the terms and conditions of the Purchase Agreement shall govern. Assignee acknowledges that Assignor makes no representation or warranty with respect to the Patents except as specifically set forth in the Purchase Agreement.

6. No Modifications. This Patent Assignment Agreement may not be supplemented, altered or modified in any manner except by a writing signed by all parties hereto.

7. Successors and Assigns. This Patent Assignment Agreement shall bind and shall inure to the benefit of the respective parties and their assigns, transferees and successors. Each Party agrees that its rights and obligations under this Patent Assignment Agreement may not be transferred or assigned, in whole or in part, directly or indirectly, to any Person without the prior written consent of the other Party (such consent not to be unreasonably withheld, conditioned or delayed); provided, however, that (a) Assignor may transfer or assign such rights and obligations under this Patent Assignment Agreement to a liquidation trust or similar vehicle under a confirmed chapter 11 plan of liquidation in the Chapter 11 Cases and (b) Assignee may transfer or assign such rights and obligations under this Patent Assignment Agreement to one or more Affiliates of Assignee, but no such assignment shall relieve Assignee of its obligations hereunder and Assignee shall in all cases remain responsible for all such obligations.

8. Notice. Any notice, request, demand, waiver, consent, approval or other communication permitted or required under this Agreement (each, a "Notice") shall be in writing, shall refer specifically to this Agreement and shall be deemed given only if delivered by hand or sent by email of a PDF attachment (with transmission confirmed) or by internationally recognized overnight delivery service that maintains records of delivery, addressed to the Parties at their respective addresses specified in this Section 8 or to such other address as the Party to whom Notice is to be given may have provided to the other Party at least five (5) days prior to such address taking effect in accordance with this Section 8. Such Notice shall be deemed to have been given as of the date delivered by hand or internationally recognized overnight delivery service or confirmed that it was received by email (with receipt confirmed by telephone). If a Notice deemed given upon receipt is given after 5:00 p.m. in the place of receipt (the Parties understand and agree that the foregoing applies only to Notice and not to copies), such Notice will be deemed given on the next succeeding Business Day.

Address for Notice.

If to Assignor, to:

NanoString Technologies, Inc.
530 Fairview Avenue North
Seattle, WA 98109
Attention: Kathy Surace-Smith
Email: ksmith@nanostring.com

with a copy (which shall not constitute effective notice) to:

Willkie Farr & Gallagher LLP
787 Seventh Avenue
New York, NY 10019
Attention: Rachel Strickland; Thomas Mark; Debra McElligott Sinclair; Tyler Born
Email: rstrickland@willkie.com; tmark@willkie.com; dsinclair@willkie.com; tborn@willkie.com

If to Assignee, to:

Bruker Spatial Biology, Inc.
c/o Bruker Corporation
40 Manning Road
Billerica, MA 01821
Attention: Office of General Counsel
Email: brent.alldredge@bruker.com

with a copy (which shall not constitute effective notice) to:

Morgan, Lewis & Bockius LLP
101 Park Ave
New York, NY 10178
Attention: Robert Dickey and Jennifer Feldsher
Email: robert.dickey@morganlewis.com; jennifer.feldsher@morganlewis.com

9. Counterparts. This Patent Assignment Agreement may be executed in one or more counterparts, each of which shall be deemed an original but both of which together will constitute one and the same instrument.

[*Remainder of this page intentionally left blank.*]

NANOSTRING TECHNOLOGIES, INC.

By: Kathy Surace-Smith
Name: Kathy Surace-Smith
Title: General Counsel

06/03/2024 Bellevue
Date and Place of Execution

STATE OF Washington)
: ss.
COUNTY OF King)

The person whose name is subscribed to the accompanying instrument is personally known to me or has proved his/her identity to me on the basis of satisfactory evidence. On May 3rd 2024, he/she appeared before me and acknowledged that he/she has read the accompanying instrument and knows the contents thereof, and that he/she executed the same as their free act and deed for the purposes set forth therein. If he/she is acting on behalf of an entity, he/she also acknowledged that he/she executed the accompanying instrument in his/her authorized capacity, and that by his/her signature on the instrument, the entity executed the same.

NOTARY PUBLIC
Residing at Shoreline

My Commission Expires: 04-01-25

ISAAC OLSON NOTARY PUBLIC 21013956 COMMISSION EXPIRES 04-01-25 STATE OF WASHINGTON

BRUKER SPATIAL BIOLOGY, INC.

By: J. Brent Alldredge
Name: J. BRENT ALLDREDGE
Title: SECRETARY

May 2 2024 Billerica, MA
Date and Place of Execution

STATE OF MA)
: ss.
COUNTY OF Middlesex)

The person whose name is subscribed to the accompanying instrument is personally known to me or has proved his/her identity to me on the basis of satisfactory evidence. On May 2 2024, he/she appeared before me and acknowledged that he/she has read the accompanying instrument and knows the contents thereof, and that he/she executed the same as their free act and deed for the purposes set forth therein. If he/she is acting on behalf of an entity, he/she also acknowledged that he/she executed the accompanying instrument in his/her authorized capacity, and that by his/her signature on the instrument, the entity executed the same.

Kirsten A. Skibbee
NOTARY PUBLIC
Residing at Peabody MA 01960

My Commission Expires: Sept 25 2026

KIRSTEN A. SKIBBEE
Notary Public
COMMONWEALTH OF MASSACHUSETTS
My Commission Expires On
September 25, 2026

SCHEDULE A

PATENTS

Title	Application No.	Application Date	Registration No.	Registration Date	Jurisdiction	Owner(s)
[MULTIVARIATE DIAGNOSTIC ASSAYS AND METHODS FOR USING SAME	2012272763	6/22/2012	2012272763	2/16/2017	Australia	NanoString Technologies, Inc.
METHODS OF TREATING BREAST CANCER WITH GEMCITABINE THERAPY	2013282391	6/28/2013			Australia	NanoString Technologies, Inc.
METHODS TO PREDICT RISK OF RECURRENCE IN NODE-POSITIVE EARLY BREAST CANCER	2014265623	5/13/2014			Australia	NanoString Technologies, Inc.
MULTIPLEXABLE TAG-BASED REPORTER SYSTEM	2014278152	6/12/2014			Australia	NanoString Technologies, Inc.
METHODS FOR DECONVOLUTION OF MIXED CELL POPULATIONS USING GENE EXPRESSION DATA	2015301244	8/4/2015			Australia	NanoString Technologies, Inc.
MULTIVALENT PROBES HAVING SINGLE NUCLEOTIDE RESOLUTION	2016315467	9/6/2016			Australia	NanoString Technologies, Inc.
MULTIVARIATE DIAGNOSTIC ASSAYS AND METHODS FOR USING SAME	2017200433	6/22/2012	2017200433	8/2/2018	Australia	NanoString Technologies, Inc.
MULTIVARIATE DIAGNOSTIC ASSAYS AND METHODS FOR USING SAME	2839705	6/22/2012			Canada	NanoString Technologies, Inc.
METHODS OF TREATING BREAST CANCER WITH GEMCITABINE THERAPY	2877378	6/28/2013			Canada	NanoString Technologies, Inc.
METHODS TO PREDICT RISK OF RECURRENCE IN NODE-POSITIVE	2912445	5/13/2014			Canada	NanoString Technologies, Inc.

EARLY BREAST CANCER						
MULTIPLEXABLE TAG-BASED REPORTER SYSTEM	2914816	6/12/2014			Canada	NanoString Technologies, Inc.
METHODS FOR DECONVOLUTION OF MIXED CELL POPULATIONS USING GENE EXPRESSION DATA	2957538	8/4/2015			Canada	NanoString Technologies, Inc.
MULTIVALENT PROBES HAVING SINGLE NUCLEOTIDE RESOLUTION	2997120	9/6/2016			Canada	NanoString Technologies, Inc.
MULTIVALENT PROBES HAVING SINGLE NUCLEOTIDE RESOLUTION	201680063151	9/6/2016			China	NanoString Technologies, Inc.
METHODS FOR DECONVOLUTION OF MIXED CELL POPULATIONS USING GENE EXPRESSION DATA	201580054736.X	8/4/2015			China	NanoString Technologies, Inc.
NANOREPORTERS AND METHODS OF MANUFACTURING AND USE THEREOF][1]	6848158	12/22/2006			European Patent Office	NanoString Technologies, Inc.
METHODS AND COMPUTER SYSTEMS FOR IDENTIFYING TARGET-SPECIFIC SEQUENCES FOR USE IN NANOREPORTERS[2]	08733186	4/10/2008			European Patent Office	NanoString Technologies, Inc.
MULTIVARIATE DIAGNOSTIC ASSAYS AND METHODS FOR USING SAME	12802554	6/22/2012			European Patent Office	NanoString Technologies, Inc.
[METHODS OF TREATING BREAST CANCER WITH GEMCITABINE THERAPY	13808764	6/28/2013			European Patent Office	NanoString Technologies, Inc.

[1] Each of the bracketed patents is abandoned.

[2] This patent application has been refused.

MULTIPLEXABLE TAG-BASED REPORTER SYSTEM	14739298	6/12/2014			European Patent Office	NanoString Technologies, Inc.
METHODS TO PREDICT RISK OF RECURRENCE IN NODE-POSITIVE EARLY BREAST CANCER	14797078	5/13/2014			European Patent Office	NanoString Technologies, Inc.
METHODS FOR DECONVOLUTION OF MIXED CELL POPULATIONS USING GENE EXPRESSION DATA	15753257	8/4/2015			European Patent Office	NanoString Technologies, Inc.
PROTEIN DETECTION VIA NANOREPORTERS	16201369	10/13/2010			European Patent Office	NanoString Technologies, Inc.
METHODS AND KITS FOR SIMULTANEOUSLY DETECTING GENE OR PROTEIN EXPRESSION IN A PLURALITY OF SAMPLE TYPES USING SELF-ASSEMBLING FLUORESCENT BARCODE NANOREPORTERS	16738632	6/30/2016			European Patent Office	NanoString Technologies, Inc.
MULTIVALENT PROBES HAVING SINGLE NUCLEOTIDE RESOLUTION	16766204	9/6/2016			European Patent Office	NanoString Technologies, Inc.
MULTIPLEXABLE TAG-BASED REPORTER SYSTEM	18176103	6/12/2014			European Patent Office	NanoString Technologies, Inc.
METHODS FOR DECONVOLUTION OF MIXED CELL POPULATIONS USING GENE EXPRESSION DATA	17113308.1	8/4/2015			Hong Kong	NanoString Technologies, Inc.
MULTIPLEXABLE TAG-BASED REPORTER SYSTEM	19127383	6/12/2014			Hong Kong	NanoString Technologies, Inc.
Obinutuzumab treatment of a dlbcl patient subgroup	20200035441	8/8/2018			South Korea	F. Hoffman-LaRoche AG and NanoString

						Technologies, Inc.[3]
MULTIVALENT PROBES HAVING SINGLE NUCLEOTIDE RESOLUTION	11201801677	9/6/2016			Singapore	NanoString Technologies, Inc.
MULTIVARIATE DIAGNOSTIC ASSAYS AND METHODS FOR USING SAME	13/530,848	6/22/2012			United States of America	NanoString Technologies, Inc.
METHODS AND COMPUTER SYSTEMS FOR IDENTIFYING TARGET-SPECIFIC SEQUENCES FOR USE IN NANOREPORTERS	13/788,113	3/7/2013			United States of America	NanoString Technologies, Inc.
METHODS OF TREATING BREAST CANCER WITH GEMCITABINE THERAPY	13/930,249	6/28/2013			United States of America	British Columbia Cancer Agency Branch; NanoString Technologies, Inc.[4]
METHODS TO PREDICT BREAST CANCER OUTCOME	14/078,009	11/12/2013			United States of America	NanoString Technologies, Inc.
MULTIPLEXABLE TAG-BASED REPORTER SYSTEM	14/303,236	6/12/2014			United States of America	NanoString Technologies, Inc.
METHODS FOR DECONVOLUTION OF MIXED CELL POPULATIONS USING GENE EXPRESSION DATA	14/817,260	8/4/2015			United States of America	NanoString Technologies, Inc.
METHODS TO PREDICT RISK OF RECURRENCE IN NODE-POSITIVE EARLY BREAST CANCER	14/890,983	5/13/2014			United States of America	NanoString Technologies, Inc.

[3] Patent application is co-owned with F. Hoffman-LaRoche AG. and Assignor only assigns Assignor's interest in the patent.

[4] Patent application is co-owned with British Columbia Cancer Agency Branch and Assignor only assigns Assignor's interest in the patent.

ENZYME- AND AMPLIFICATION-FREE SEQUENCING	14/946,386	11/19/2015			United States of America	NanoString Technologies, Inc.
METHODS AND KITS FOR SIMULTANEOUSLY DETECTING GENE OR PROTEIN EXPRESSION IN A PLURALITY OF SAMPLE TYPES USING SELF-ASSEMBLING FLUORESCENT BARCODE NANOREPORTERS	15/197,980	6/30/2016			United States of America	NanoString Technologies, Inc.
MULTIVALENT PROBES HAVING SINGLE NUCLEOTIDE RESOLUTION	15/257,213	9/6/2016			United States of America	NanoString Technologies, Inc.
METHODS FOR DETECTING TARGET NUCLEIC ACIDS IN A SAMPLE	15/597,055	5/16/2017			United States of America	NanoString Technologies, Inc.
COMPOSITIONS AND METHODS FOR THE DETECTION OF GENOMIC FEATURES	15/729,421	10/10/2017			United States of America	NanoString Technologies, Inc.
NANOREPORTERS AND METHODS OF MANUFACTURING AND USE THEREOF[5]	15/859,949	1/2/2018			United States of America	The Institute for Systems Biology; NanoString Technologies, Inc.
STABLE NANOREPORTERS	16/103,369	8/14/2018			United States of America	NanoString Technologies, Inc.
BIOMOLECULAR PROBES AND METHODS OF DETECTING GENE AND PROTEIN EXPRESSION	16/272,487	2/11/2019			United States of America	NanoString Technologies, Inc.
METHODS FOR DETECTING TARGET NUCLEIC ACIDS IN A SAMPLE	16/417,109	5/20/2019			United States of America	NanoString Technologies, Inc.

[5] Patent is co-owned with The Institute for Systems Biology and Assignor only assigns Assignor's interest in the patent.

ENZYME- AND AMPLIFICATION-FREE SEQUENCING	16/528,760	8/1/2019			United States of America	NanoString Technologies, Inc.
CHEMICAL COMPOSITIONS AND METHODS OF USE][6]	17/816,233	7/29/2022			United States of America	NanoString Technologies, Inc.
NANOREPORTERS AND METHODS OF MANUFACTURING AND USE THEREOF[7]	13/794,424	3/11/2013	9,371,563	6/21/2016	United States	The Institute for Systems Biology; NanoString Technologies, Inc.
NANOREPORTERS AND METHODS OF MANUFACTURING AND USE THEREOF[8]	15/160,376	5/20/2016	9,890,419	2/13/2018	United States	The Institute for Systems Biology; NanoString Technologies, Inc.
NANOREPORTERS AND METHODS OF MANUFACTURING AND USE THEREOF[9]	2013203290	12/22/2006	2013203290	8/18/2016	Australia	The Institute for Systems Biology; NanoString Technologies, Inc.
NANOREPORTERS AND METHODS OF MANUFACTURING AND USE THEREOF[10]	2006330830	12/22/2006	2006330830	4/26/2013	Australia	The Institute for Systems Biology; NanoString Technologies, Inc.
NANOREPORTERS AND METHODS OF MANUFACTURING AND USE THEREOF[11]	2640385	12/22/2006	2640385	7/15/2014	Canada	The Institute for Systems Biology; NanoString Technologies, Inc.

[6] Each of the bracketed patents is abandoned.

[7] Patent is co-owned with The Institute for Systems Biology and Assignor only assigns Assignor's interest in the patent.

[8] Patent is co-owned with The Institute for Systems Biology and Assignor only assigns Assignor's interest in the patent.

[9] Patent is co-owned with The Institute for Systems Biology and Assignor only assigns Assignor's interest in the patent.

[10] Patent is co-owned with The Institute for Systems Biology and Assignor only assigns Assignor's interest in the patent.

[11] Patent is co-owned with The Institute for Systems Biology and Assignor only assigns Assignor's interest in the patent.

NANOREPORTERS AND METHODS OF MANUFACTURING AND USE THEREOF[12]	06848157.1	12/22/2006	1963531	9/21/2011	Switzerland	The Institute for Systems Biology; NanoString Technologies, Inc.
NANOREPORTERS AND METHODS OF MANUFACTURING AND USE THEREOF[13]	06848157.1	12/22/2006	1963531	9/21/2011	Germany	The Institute for Systems Biology; NanoString Technologies, Inc.
NANOREPORTERS AND METHODS OF MANUFACTURING AND USE THEREOF[14]	06848157.1	12/22/2006	1963531	9/21/2011	European Patent Office	The Institute for Systems Biology; NanoString Technologies, Inc.
NANOREPORTERS AND METHODS OF MANUFACTURING AND USE THEREOF[15]	06848157.1	12/22/2006	1963531	9/21/2011	Spain	The Institute for Systems Biology; NanoString Technologies, Inc.
NANOREPORTERS AND METHODS OF MANUFACTURING AND USE THEREOF[16]	06848157.1	12/22/2006	1963531	9/21/2011	France	The Institute for Systems Biology; NanoString Technologies, Inc.
NANOREPORTERS AND METHODS OF MANUFACTURING AND USE THEREOF[17]	06848157.1	12/22/2006	1963531	9/21/2011	United Kingdom	The Institute for Systems Biology; NanoString Technologies, Inc.

[12] Patent is co-owned with The Institute for Systems Biology and Assignor only assigns Assignor's interest in the patent.

[13] Patent is co-owned with The Institute for Systems Biology and Assignor only assigns Assignor's interest in the patent.

[14] Patent is co-owned with The Institute for Systems Biology and Assignor only assigns Assignor's interest in the patent.

[15] Patent is co-owned with The Institute for Systems Biology and Assignor only assigns Assignor's interest in the patent.

[16] Patent is co-owned with The Institute for Systems Biology and Assignor only assigns Assignor's interest in the patent.

[17] Patent is co-owned with The Institute for Systems Biology and Assignor only assigns Assignor's interest in the patent.

NANOREPORTERS AND METHODS OF MANUFACTURING AND USE THEREOF[18]	06848157.1	12/22/2006	1963531	9/21/2011	Ireland	The Institute for Systems Biology; NanoString Technologies, Inc.
NANOREPORTERS AND METHODS OF MANUFACTURING AND USE THEREOF[19]	06848157.1	12/22/2006	1963531	9/21/2011	Italy	The Institute for Systems Biology; NanoString Technologies, Inc.
NANOREPORTERS AND METHODS OF MANUFACTURING AND USE THEREOF[20]	2008-547662	12/22/2006	5537034	5/9/2014	Japan	The Institute for Systems Biology; NanoString Technologies, Inc.
COMPOSITIONS COMPRISING ORIENTED, IMMOBILIZED MACROMOLECULES AND METHODS FOR THEIR PREPARATION	11/645,270	12/22/2006	8,986,926	3/24/2015	United States	NanoString Technologies, Inc.
COMPOSITIONS COMPRISING ORIENTED, IMMOBILIZED MACROMOLECULES AND METHODS FOR THEIR PREPARATION	2006330834	12/22/2006	2006330834	12/24/2013	Australia	NanoString Technologies, Inc.
COMPOSITIONS COMPRISING ORIENTED, IMMOBILIZED MACROMOLECULES AND METHODS FOR THEIR PREPARATION	2635215	12/22/2006	2635215	8/30/2016	Canada	NanoString Technologies, Inc.
COMPOSITIONS COMPRISING ORIENTED, IMMOBILIZED MACROMOLECULES AND METHODS FOR THEIR PREPARATION	06848160.5	12/22/2006	1963500	2/13/2013	Switzerland	NanoString Technologies, Inc.
COMPOSITIONS COMPRISING ORIENTED, IMMOBILIZED MACROMOLECULES AND	06848160.5	12/22/2006	1963500	2/13/2013	Germany	NanoString Technologies, Inc.

[18] Patent is co-owned with The Institute for Systems Biology and Assignor only assigns Assignor's interest in the patent.

[19] Patent is co-owned with The Institute for Systems Biology and Assignor only assigns Assignor's interest in the patent.

[20] Patent is co-owned with The Institute for Systems Biology and Assignor only assigns Assignor's interest in the patent.

METHODS FOR THEIR PREPARATION						
COMPOSITIONS COMPRISING ORIENTED, IMMOBILIZED MACROMOLECULES AND METHODS FOR THEIR PREPARATION	06848160.5	12/22/2006	1963500	2/13/2013	European Patent Office	NanoString Technologies, Inc.
COMPOSITIONS COMPRISING ORIENTED, IMMOBILIZED MACROMOLECULES AND METHODS FOR THEIR PREPARATION	06848160.5	12/22/2006	1963500	2/13/2013	Spain	NanoString Technologies, Inc.
COMPOSITIONS COMPRISING ORIENTED, IMMOBILIZED MACROMOLECULES AND METHODS FOR THEIR PREPARATION	06848160.5	12/22/2006	1963500	2/13/2013	France	NanoString Technologies, Inc.
COMPOSITIONS COMPRISING ORIENTED, IMMOBILIZED MACROMOLECULES AND METHODS FOR THEIR PREPARATION	06848160.5	12/22/2006	1963500	2/13/2013	United Kingdom	NanoString Technologies, Inc.
COMPOSITIONS COMPRISING ORIENTED, IMMOBILIZED MACROMOLECULES AND METHODS FOR THEIR PREPARATION	06848160.5	12/22/2006	1963500	2/13/2013	Ireland	NanoString Technologies, Inc.
COMPOSITIONS COMPRISING ORIENTED, IMMOBILIZED MACROMOLECULES AND METHODS FOR THEIR PREPARATION	06848160.5	12/22/2006	1963500	2/13/2013	Italy	NanoString Technologies, Inc.
COMPOSITIONS COMPRISING ORIENTED, IMMOBILIZED MACROMOLECULES AND METHODS FOR THEIR PREPARATION	2008-547664	12/22/2006	5700911	2/27/2015	Japan	NanoString Technologies, Inc.
SYSTEMS AND METHODS FOR ANALYZING NANOREPORTERS	11/805,273	5/21/2007	7,941,279	5/10/2011	United States	NanoString Technologies, Inc.
SYSTEMS AND METHODS FOR ANALYZING NANOREPORTERS	2007268027	5/21/2007	2007268027	11/22/2012	Australia	NanoString Technologies, Inc.
SYSTEMS AND METHODS FOR ANALYZING NANOREPORTERS	2653095	5/21/2007	2653095	7/16/2013	Canada	NanoString Technologies, Inc.
SYSTEMS AND METHODS FOR ANALYZING NANOREPORTERS	07795152.3	5/21/2007	2030011	2/1/2017	Switzerland	NanoString Technologies, Inc.

SYSTEMS AND METHODS FOR ANALYZING NANOREPORTERS	07795152.3	5/21/2007	2030011	2/1/2017	Germany	NanoString Technologies, Inc.
SYSTEMS AND METHODS FOR ANALYZING NANOREPORTERS	07795152.3	5/21/2007	2030011	2/1/2017	European Patent Office	NanoString Technologies, Inc.
SYSTEMS AND METHODS FOR ANALYZING NANOREPORTERS	07795152.3	5/21/2007	2030011	2/1/2017	Spain	NanoString Technologies, Inc.
SYSTEMS AND METHODS FOR ANALYZING NANOREPORTERS	07795152.3	5/21/2007	2030011	2/1/2017	France	NanoString Technologies, Inc.
SYSTEMS AND METHODS FOR ANALYZING NANOREPORTERS	07795152.3	5/21/2007	2030011	2/1/2017	United Kingdom	NanoString Technologies, Inc.
SYSTEMS AND METHODS FOR ANALYZING NANOREPORTERS	07795152.3	5/21/2007	2030011	2/1/2017	Ireland	NanoString Technologies, Inc.
SYSTEMS AND METHODS FOR ANALYZING NANOREPORTERS	07795152.3	5/21/2007	2030011	2/1/2017	Italy	NanoString Technologies, Inc.
SYSTEMS AND METHODS FOR ANALYZING NANOREPORTERS	2009-512084	5/21/2007	5081232	9/7/2012	Japan	NanoString Technologies, Inc.
METHODS FOR IDENTIFYING TARGET-SPECIFIC SEQUENCES FOR USE IN NANOREPORTERS	12/100,990	4/10/2008	8,415,102	4/9/2013	United States	NanoString Technologies, Inc.
METHODS AND COMPUTER SYSTEMS FOR IDENTIFYING TARGET-SPECIFIC SEQUENCES FOR USE IN NANOREPORTERS	2008237018	4/10/2008	2008237018	7/17/2014	Australia	NanoString Technologies, Inc.
METHODS AND COMPUTER SYSTEMS FOR IDENTIFYING TARGET-SPECIFIC SEQUENCES FOR USE IN NANOREPORTERS	2687292	4/10/2008	2687292	7/4/2017	Canada	NanoString Technologies, Inc.
METHODS AND COMPUTER SYSTEMS FOR IDENTIFYING TARGET-SPECIFIC SEQUENCES FOR USE IN NANOREPORTERS	2010-503214	4/10/2008	5555157	6/6/2014	Japan	NanoString Technologies, Inc.
STABLE NANOREPORTERS	12/541,131	8/13/2009	8,519,115	8/27/2013	United States	NanoString Technologies, Inc.
STABLE NANOREPORTERS	13/957,029	8/1/2013	9,376,712	6/28/2016	United States	NanoString Technologies, Inc.
STABLE NANOREPORTERS	15/082,398	3/28/2016	10,077,466	9/18/2018	United States	NanoString Technologies, Inc.
STABLE NANOREPORTERS	2015201993	8/13/2009	2015201993	1/11/2018	Australia	NanoString Technologies, Inc.

STABLE NANOREPORTERS	16194404.6	8/13/2009	3162900	7/18/2018	Switzerland	NanoString Technologies, Inc.
STABLE NANOREPORTERS	16194404.6	8/13/2009	3162900	7/18/2018	Germany	NanoString Technologies, Inc.
STABLE NANOREPORTERS	16194404.6	8/13/2009	3162900	7/18/2018	European Patent Office	NanoString Technologies, Inc.
STABLE NANOREPORTERS	16194404.6	8/13/2009	3162900	7/18/2018	Spain	NanoString Technologies, Inc.
STABLE NANOREPORTERS	16194404.6	8/13/2009	3162900	7/18/2018	France	NanoString Technologies, Inc.
STABLE NANOREPORTERS	16194404.6	8/13/2009	3162900	7/18/2018	United Kingdom	NanoString Technologies, Inc.
STABLE NANOREPORTERS	16194404.6	8/13/2009	3162900	7/18/2018	Ireland	NanoString Technologies, Inc.
STABLE NANOREPORTERS	16194404.6	8/13/2009	3162900	7/18/2018	Italy	NanoString Technologies, Inc.
STABLE NANOREPORTERS	2015-76699	8/13/2009	6246155	11/24/2017	Japan	NanoString Technologies, Inc.
STABLE NANOREPORTERS	15/082,436	3/28/2016	9,856,519	1/2/2018	United States	NanoString Technologies, Inc.
STABLE NANOREPORTERS	2009281836	8/13/2009	2009281836	6/4/2015	Australia	NanoString Technologies, Inc.
STABLE NANOREPORTERS	2733609	8/13/2009	2733609	3/6/2018	Canada	NanoString Technologies, Inc.
STABLE NANOREPORTERS	09791508.6	8/13/2009	2331704	11/30/2016	Switzerland	NanoString Technologies, Inc.
STABLE NANOREPORTERS	09791508.6	8/13/2009	2331704	11/30/2016	Germany	NanoString Technologies, Inc.
STABLE NANOREPORTERS	09791508.6	8/13/2009	2331704	11/30/2016	European Patent Office	NanoString Technologies, Inc.
STABLE NANOREPORTERS	09791508.6	8/13/2009	2331704	11/30/2016	Spain	NanoString Technologies, Inc.
STABLE NANOREPORTERS	09791508.6	8/13/2009	2331704	11/30/2016	France	NanoString Technologies, Inc.
STABLE NANOREPORTERS	09791508.6	8/13/2009	2331704	11/30/2016	United Kingdom	NanoString Technologies, Inc.
STABLE NANOREPORTERS	09791508.6	8/13/2009	2331704	11/30/2016	Ireland	NanoString Technologies, Inc.

STABLE NANOREPORTERS	09791508.6	8/13/2009	2331704	11/30/2016	Italy	NanoString Technologies, Inc.
STABLE NANOREPORTERS	2011-523183	8/13/2009	5836803	11/13/2015	Japan	NanoString Technologies, Inc.
STABLE NANOREPORTERS	09791508.6	8/13/2009	2331704	11/30/2016	Netherlands	NanoString Technologies, Inc.
PROTEIN DETECTION VIA NANOREPORTERS	12/904,078	10/13/2010	9,714,937	7/25/2017	United States	NanoString Technologies, Inc.
PROTEIN DETECTION VIA NANOREPORTERS	14/814,216	7/30/2015	9,995,739	6/12/2018	United States	NanoString Technologies, Inc.
PROTEIN DETECTION VIA NANOREPORTERS	2015261558	10/13/2010	2015261558	1/11/2018	Australia	NanoString Technologies, Inc.
PROTEIN DETECTION VIA NANOREPORTERS	2016-81763	10/13/2010	6225212	10/13/2017	Japan	NanoString Technologies, Inc.
PROTEIN DETECTION VIA NANOREPORTERS	2010306862	10/13/2010	2010306862	12/10/2015	Australia	NanoString Technologies, Inc.
PROTEIN DETECTION VIA NANOREPORTERS	2775613	10/13/2010	2775613	6/12/2018	Canada	NanoString Technologies, Inc.
PROTEIN DETECTION VIA NANOREPORTERS	10824048.2	10/13/2010	2488876	3/1/2017	Switzerland	NanoString Technologies, Inc.
PROTEIN DETECTION VIA NANOREPORTERS	10824048.2	10/13/2010	2488876	3/1/2017	Germany	NanoString Technologies, Inc.
PROTEIN DETECTION VIA NANOREPORTERS	10824048.2	10/13/2010	2488876	3/1/2017	European Patent Office	NanoString Technologies, Inc.
PROTEIN DETECTION VIA NANOREPORTERS	10824048.2	10/13/2010	2488876	3/1/2017	Spain	NanoString Technologies, Inc.
PROTEIN DETECTION VIA NANOREPORTERS	10824048.2	10/13/2010	2488876	3/1/2017	France	NanoString Technologies, Inc.
PROTEIN DETECTION VIA NANOREPORTERS	10824048.2	10/13/2010	2488876	3/1/2017	United Kingdom	NanoString Technologies, Inc.
PROTEIN DETECTION VIA NANOREPORTERS	10824048.2	10/13/2010	2488876	3/1/2017	Ireland	NanoString Technologies, Inc.
PROTEIN DETECTION VIA NANOREPORTERS	10824048.2	10/13/2010	2488876	3/1/2017	Italy	NanoString Technologies, Inc.
PROTEIN DETECTION VIA NANOREPORTERS	2012-534336	10/13/2010	5954876	6/24/2016	Japan	NanoString Technologies, Inc.

COMPOSITIONS AND METHODS FOR THE DETECTION OF SMALL RNAS	13/025,458	2/11/2011	9,714,446	7/25/2017	United States	NanoString Technologies, Inc.
COMPOSITIONS AND METHODS FOR THE DETECTION OF SMALL RNAS	2011215753	2/11/2011	2011215753	12/17/2015	Australia	NanoString Technologies, Inc.
COMPOSITIONS AND METHODS FOR THE DETECTION OF SMALL RNAS	2785529	2/11/2011	2785529	1/8/2019	Canada	NanoString Technologies, Inc.
COMPOSITIONS AND METHODS FOR THE DETECTION OF SMALL RNAS	11742859.9	2/11/2011	2516681	10/18/2017	Switzerland	NanoString Technologies, Inc.
COMPOSITIONS AND METHODS FOR THE DETECTION OF SMALL RNAS	11742859.9	2/11/2011	2516681	10/18/2017	Germany	NanoString Technologies, Inc.
COMPOSITIONS AND METHODS FOR THE DETECTION OF SMALL RNAS	11742859.9	2/11/2011	2516681	10/18/2017	European Patent Office	NanoString Technologies, Inc.
COMPOSITIONS AND METHODS FOR THE DETECTION OF SMALL RNAS	11742859.9	2/11/2011	2516681	10/18/2017	Spain	NanoString Technologies, Inc.
COMPOSITIONS AND METHODS FOR THE DETECTION OF SMALL RNAS	11742859.9	2/11/2011	2516681	10/18/2017	France	NanoString Technologies, Inc.
COMPOSITIONS AND METHODS FOR THE DETECTION OF SMALL RNAS	11742859.9	2/11/2011	2516681	10/18/2017	United Kingdom	NanoString Technologies, Inc.
COMPOSITIONS AND METHODS FOR THE DETECTION OF SMALL RNAS	11742859.9	2/11/2011	2516681	10/18/2017	Ireland	NanoString Technologies, Inc.
COMPOSITIONS AND METHODS FOR THE DETECTION OF SMALL RNAS	11742859.9	2/11/2011	2516681	10/18/2017	Italy	NanoString Technologies, Inc.
COMPOSITIONS AND METHODS FOR THE DETECTION OF SMALL RNAS	2012-553031	2/11/2011	5914362	4/8/2016	Japan	NanoString Technologies, Inc.
COMPOSITIONS AND METHODS FOR THE DETECTION OF GENOMIC FEATURES	11756928.5	3/16/2011	2547795	1/14/2015	Switzerland	NanoString Technologies, Inc.
COMPOSITIONS AND METHODS FOR THE DETECTION OF GENOMIC FEATURES	11756928.5	3/16/2011	2547795	1/14/2015	Germany	NanoString Technologies, Inc.

COMPOSITIONS AND METHODS FOR THE DETECTION OF GENOMIC FEATURES	11756928.5	3/16/2011	2547795	1/14/2015	European Patent Office	NanoString Technologies, Inc.
COMPOSITIONS AND METHODS FOR THE DETECTION OF GENOMIC FEATURES	11756928.5	3/16/2011	2547795	1/14/2015	France	NanoString Technologies, Inc.
COMPOSITIONS AND METHODS FOR THE DETECTION OF GENOMIC FEATURES	11756928.5	3/16/2011	2547795	1/14/2015	United Kingdom	NanoString Technologies, Inc.
COMPOSITIONS AND METHODS FOR DIAGNOSING CANCER	14/007,586	3/28/2012	9,758,834	9/12/2017	United States	NanoString Technologies, Inc.
METHODS AND APPARATUSES FOR GENE PURIFICATION AND IMAGING	14/948,776	11/23/2015	10,246,700	4/2/2019	United States	NanoString Technologies, Inc.
METHODS AND APPARATUSES FOR GENE PURIFICATION AND IMAGING	16/272,073	2/11/2019	11,098,301	8/24/2021	United States	NanoString Technologies, Inc.
METHODS AND APPARATUSES FOR GENE PURIFICATION AND IMAGING	2015353747	11/23/2015	2015353747	6/10/2021	Australia	NanoString Technologies, Inc.
METHODS AND APPARATUSES FOR GENE PURIFICATION AND IMAGING	2968519	11/23/2015			Canada	NanoString Technologies, Inc.
METHODS AND APPARATUSES FOR GENE PURIFICATION AND IMAGING	15816281.8	11/23/2015	3223947	10/30/2019	Switzerland	NanoString Technologies, Inc.
METHODS AND APPARATUSES FOR GENE PURIFICATION AND IMAGING	201580074230.5	11/23/2015	ZL201580074230.5	4/2/2021	China	NanoString Technologies, Inc.
METHODS AND APPARATUSES FOR GENE PURIFICATION AND IMAGING	15816281.8	11/23/2015	3223947	10/30/2019	Germany	NanoString Technologies, Inc.
METHODS AND APPARATUSES FOR GENE PURIFICATION AND IMAGING	15816281.8	11/23/2015	3223947	10/30/2019	European Patent Office	NanoString Technologies, Inc.
METHODS AND APPARATUSES FOR GENE PURIFICATION AND IMAGING	15816281.8	11/23/2015	3223947	10/30/2019	Spain	NanoString Technologies, Inc.
METHODS AND APPARATUSES FOR GENE PURIFICATION AND IMAGING	15816281.8	11/23/2015	3223947	10/30/2019	France	NanoString Technologies, Inc.

METHODS AND APPARATUSES FOR GENE PURIFICATION AND IMAGING	15816281.8	11/23/2015	3223947	10/30/2019	United Kingdom	NanoString Technologies, Inc.
METHODS AND APPARATUSES FOR GENE PURIFICATION AND IMAGING	18101562.6	11/23/2015	1242251	11/20/2020	Hong Kong	NanoString Technologies, Inc.
METHODS AND APPARATUSES FOR GENE PURIFICATION AND IMAGING	15816281.8	11/23/2015	3223947	10/30/2019	Ireland	NanoString Technologies, Inc.
METHODS AND APPARATUSES FOR GENE PURIFICATION AND IMAGING	15816281.8	11/23/2015	3223947	10/30/2019	Italy	NanoString Technologies, Inc.
METHODS AND APPARATUSES FOR GENE PURIFICATION AND IMAGING	2017-527737	11/23/2015	7144142	9/29/2022	Japan	NanoString Technologies, Inc.
METHODS AND APPARATUSES FOR GENE PURIFICATION AND IMAGING	10-2017-7017400	11/23/2015	102602507000 0	11/10/2023	Republic of Korea	NanoString Technologies, Inc.
METHODS AND APPARATUSES FOR GENE PURIFICATION AND IMAGING	11201704177S	11/23/2015	11201704177S	4/3/2023	Singapore	NanoString Technologies, Inc.
CHEMICAL COMPOSITIONS AND METHODS OF USE	18/172,771	2/22/2023			United States	NanoString Technologies, Inc.
ENZYME- AND AMPLIFICATION-FREE SEQUENCING	2019275665	11/19/2015	2019275665	12/1/2022	Australia	NanoString Technologies, Inc.
ENZYME- AND AMPLIFICATION-FREE SEQUENCING	20151469.2	11/19/2015	3696280	1/5/2022	Switzerland	NanoString Technologies, Inc.
ENZYME- AND AMPLIFICATION-FREE SEQUENCING	202110629754.3	11/19/2015			China	NanoString Technologies, Inc.
ENZYME- AND AMPLIFICATION-FREE SEQUENCING	20151469.2	11/19/2015	3696280	1/5/2022	Germany	NanoString Technologies, Inc.
ENZYME- AND AMPLIFICATION-FREE SEQUENCING	20151469.2	11/19/2015	3696280	1/5/2022	European Patent Office	NanoString Technologies, Inc.
ENZYME- AND AMPLIFICATION-FREE SEQUENCING	20151469.2	11/19/2015	3696280	1/5/2022	Spain	NanoString Technologies, Inc.
ENZYME- AND AMPLIFICATION-FREE SEQUENCING	20151469.2	11/19/2015	3696280	1/5/2022	France	NanoString Technologies, Inc.
ENZYME- AND AMPLIFICATION-FREE SEQUENCING	20151469.2	11/19/2015	3696280	1/5/2022	United Kingdom	NanoString Technologies, Inc.

ENZYME- AND AMPLIFICATION-FREE SEQUENCING	42021024485.1	11/19/2015	40034588	7/29/2022	Hong Kong	NanoString Technologies, Inc.
ENZYME- AND AMPLIFICATION-FREE SEQUENCING	20151469.2	11/19/2015	3696280	1/5/2022	Ireland	NanoString Technologies, Inc.
ENZYME- AND AMPLIFICATION-FREE SEQUENCING	20151469.2	11/19/2015	3696280	1/5/2022	Italy	NanoString Technologies, Inc.
ENZYME- AND AMPLIFICATION-FREE SEQUENCING	2020-040296	11/19/2015	6959378	10/11/2021	Japan	NanoString Technologies, Inc.
ENZYME- AND AMPLIFICATION-FREE SEQUENCING	10-2020-7011298	11/19/2015	10-2298387	8/31/2021	Republic of Korea	NanoString Technologies, Inc.
ENZYME- AND AMPLIFICATION-FREE SEQUENCING	10202251281Q	11/19/2015			Singapore	NanoString Technologies, Inc.
ENZYME- AND AMPLIFICATION-FREE SEQUENCING	2022271472	11/19/2015			Australia	NanoString Technologies, Inc.
ENZYME- AND AMPLIFICATION-FREE SEQUENCING	22150167.9	11/19/2015			European Patent Office	NanoString Technologies, Inc.
ENZYME- AND AMPLIFICATION-FREE SEQUENCING	42023067045.7	11/19/2015			Hong Kong	NanoString Technologies, Inc.
ENZYME- AND AMPLIFICATION-FREE SEQUENCING	2021-164668	11/19/2015	7244601	3/13/2023	Japan	NanoString Technologies, Inc.
ENZYME- AND AMPLIFICATION-FREE SEQUENCING	10-2021-7027822	11/19/2015	2417849	7/1/2022	Republic of Korea	NanoString Technologies, Inc.
ENZYME- AND AMPLIFICATION-FREE SEQUENCING	2023-036774	11/19/2015			Japan	NanoString Technologies, Inc.
ENZYME- AND AMPLIFICATION-FREE SEQUENCING	10-2022-7022673	11/19/2015			Republic of Korea	NanoString Technologies, Inc.
ENZYME- AND AMPLIFICATION-FREE SEQUENCING	2015349870	11/19/2015	2015349870	1/9/2020	Australia	NanoString Technologies, Inc.
ENZYME- AND AMPLIFICATION-FREE SEQUENCING	2968376	11/19/2015	2968376	6/23/2020	Canada	NanoString Technologies, Inc.
ENZYME- AND AMPLIFICATION-FREE SEQUENCING	15801655.0	11/19/2015	3221469	1/15/2020	Switzerland	NanoString Technologies, Inc.
ENZYME- AND AMPLIFICATION-FREE SEQUENCING	201580073880.8	11/19/2015	ZL201580073880.8	6/8/2021	China	NanoString Technologies, Inc.
ENZYME- AND AMPLIFICATION-FREE SEQUENCING	15801655.0	11/19/2015	3221469	1/15/2020	Germany	NanoString Technologies, Inc.
ENZYME- AND AMPLIFICATION-FREE SEQUENCING	15801655.0	11/19/2015	3221469	1/15/2020	European Patent Office	NanoString Technologies, Inc.

ENZYME- AND AMPLIFICATION-FREE SEQUENCING	15801655.0	11/19/2015	3221469	1/15/2020	Spain	NanoString Technologies, Inc.
ENZYME- AND AMPLIFICATION-FREE SEQUENCING	15801655.0	11/19/2015	3221469	1/15/2020	France	NanoString Technologies, Inc.
ENZYME- AND AMPLIFICATION-FREE SEQUENCING	15801655.0	11/19/2015	3221469	1/15/2020	United Kingdom	NanoString Technologies, Inc.
ENZYME- AND AMPLIFICATION-FREE SEQUENCING	18101561.7	11/19/2015	1242379	9/18/2020	Hong Kong	NanoString Technologies, Inc.
ENZYME- AND AMPLIFICATION-FREE SEQUENCING	15801655.0	11/19/2015	3221469	1/15/2020	Ireland	NanoString Technologies, Inc.
ENZYME- AND AMPLIFICATION-FREE SEQUENCING	15801655.0	11/19/2015	3221469	1/15/2020	Italy	NanoString Technologies, Inc.
ENZYME- AND AMPLIFICATION-FREE SEQUENCING	2017-527209	11/19/2015	6674951	3/11/2020	Japan	NanoString Technologies, Inc.
ENZYME- AND AMPLIFICATION-FREE SEQUENCING	10-2017-7016946	11/19/2015	2105236	4/21/2020	Republic of Korea	NanoString Technologies, Inc.
ENZYME- AND AMPLIFICATION-FREE SEQUENCING	11201704098V	11/19/2015	11201704098V	12/23/2022	Singapore	NanoString Technologies, Inc.
SIMULTANEOUS QUANTIFICATION OF A PLURALITY OF PROTEINS IN A USER-DEFINED REGION OF A CROSS-SECTIONED TISSUE[21]	15/211,236	7/15/2016	10,501,777	12/10/2019	United States	NanoString Technologies, Inc.; The Board of Regents of the University of Texas System
SIMULTANEOUS QUANTIFICATION OF A PLURALITY OF PROTEINS IN A USER-DEFINED REGION OF A CROSS-SECTIONED TISSUE[22]	16/596,587	10/8/2019			United States	NanoString Technologies, Inc.; The Board of Regents of the University of Texas System

[21] Terminal disclaimers exist between U.S. patent no. 10,501,777 (SIMULTANEOUS QUANTIFICATION OF A PLURALITY OF PROTEINS IN A USER-DEFINED REGION OF A CROSS-SECTIONED TISSUE) and U.S. patent no. 10,640,816 (SIMULTANEOUS QUANTIFICATION OF GENE EXPRESSION IN A USER-DEFINED REGION OF A CROSS-SECTIONED TISSUE). Patent is also co-owned with The Board of Regents of the University of Texas System and Assignor only assigns Assignor's interest in the patent.

[22] Patent is co-owned with The Board of Regents of the University of Texas System and Assignor only assigns Assignor's interest in the patent.

SIMULTANEOUS QUANTIFICATION OF A PLURALITY OF PROTEINS IN A USER-DEFINED REGION OF A CROSS-SECTIONED TISSUE[23]	2021203155	7/15/2016			Australia	NanoString Technologies, Inc.; The Board of Regents of the University of Texas System
SIMULTANEOUS QUANTIFICATION OF A PLURALITY OF PROTEINS IN A USER-DEFINED REGION OF A CROSS-SECTIONED TISSUE[24]	24150045.3	7/15/2016			European Patent Office	NanoString Technologies, Inc. ; The Board of Regents of the University of Texas System
SIMULTANEOUS QUANTIFICATION OF A PLURALITY OF PROTEINS IN A USER-DEFINED REGION OF A CROSS-SECTIONED TISSUE[25]	2021-178589	7/15/2016			Japan	NanoString Technologies, Inc.; The Board of Regents of the University of Texas System
SIMULTANEOUS QUANTIFICATION OF A PLURALITY OF PROTEINS IN A USER-DEFINED REGION OF A CROSS-SECTIONED TISSUE[26]	10202107055S	7/15/2016			Singapore	NanoString Technologies, Inc.; The Board of Regents of the University of Texas System
SIMULTANEOUS QUANTIFICATION OF A PLURALITY OF PROTEINS IN A USER-DEFINED REGION OF A CROSS-SECTIONED TISSUE[27]	2016297513	7/15/2016	2016297513	6/10/2021	Australia	NanoString Technologies, Inc.; The Board of Regents of the University of Texas System

[23] Patent is co-owned with The Board of Regents of the University of Texas System and Assignor only assigns Assignor's interest in the patent.

[24] Patent is co-owned with The Board of Regents of the University of Texas System and Assignor only assigns Assignor's interest in the patent.

[25] Patent is co-owned with The Board of Regents of the University of Texas System and Assignor only assigns Assignor's interest in the patent.

[26] Patent is co-owned with The Board of Regents of the University of Texas System and Assignor only assigns Assignor's interest in the patent.

[27] Patent is co-owned with The Board of Regents of the University of Texas System and Assignor only assigns Assignor's interest in the patent.

SIMULTANEOUS QUANTIFICATION OF A PLURALITY OF PROTEINS IN A USER-DEFINED REGION OF A CROSS-SECTIONED TISSUE[28]	2992480	7/15/2016			Canada	NanoString Technologies, Inc.; The Board of Regents of the University of Texas System
SIMULTANEOUS QUANTIFICATION OF A PLURALITY OF PROTEINS IN A USER-DEFINED REGION OF A CROSS-SECTIONED TISSUE[29]	16742554.5	7/15/2016	3325649	1/3/2024	Switzerland	NanoString Technologies, Inc.; The Board of Regents of the University of Texas System
SIMULTANEOUS QUANTIFICATION OF A PLURALITY OF PROTEINS IN A USER-DEFINED REGION OF A CROSS-SECTIONED TISSUE[30]	201680054079.3	7/15/2016			China	NanoString Technologies, Inc.; The Board of Regents of the University of Texas System
SIMULTANEOUS QUANTIFICATION OF A PLURALITY OF PROTEINS IN A USER-DEFINED REGION OF A CROSS-SECTIONED TISSUE[31]	16742554.5	7/15/2016	3325649	1/3/2024	Germany	NanoString Technologies, Inc.; The Board of Regents of the University of Texas System
SIMULTANEOUS QUANTIFICATION OF A PLURALITY OF PROTEINS IN A USER-DEFINED REGION OF A CROSS-SECTIONED TISSUE[32]	16742554.5	7/15/2016	3325649	1/3/2024	European Patent Office	NanoString Technologies, Inc.; The Board of Regents of the University of Texas System

[28] Patent is co-owned with The Board of Regents of the University of Texas System and Assignor only assigns Assignor's interest in the patent.

[29] Patent is co-owned with The Board of Regents of the University of Texas System and Assignor only assigns Assignor's interest in the patent.

[30] Patent is co-owned with The Board of Regents of the University of Texas System and Assignor only assigns Assignor's interest in the patent.

[31] Patent is co-owned with The Board of Regents of the University of Texas System and Assignor only assigns Assignor's interest in the patent.

[32] Patent is co-owned with The Board of Regents of the University of Texas System and Assignor only assigns Assignor's interest in the patent.

SIMULTANEOUS QUANTIFICATION OF A PLURALITY OF PROTEINS IN A USER-DEFINED REGION OF A CROSS-SECTIONED TISSUE[33]	16742554.5	7/15/2016	3325649	1/3/2024	Spain	NanoString Technologies, Inc.; The Board of Regents of the University of Texas System
SIMULTANEOUS QUANTIFICATION OF A PLURALITY OF PROTEINS IN A USER-DEFINED REGION OF A CROSS-SECTIONED TISSUE[34]	16742554.5	7/15/2016	3325649	1/3/2024	France	NanoString Technologies, Inc.; The Board of Regents of the University of Texas System
SIMULTANEOUS QUANTIFICATION OF A PLURALITY OF PROTEINS IN A USER-DEFINED REGION OF A CROSS-SECTIONED TISSUE[35]	16742554.5	7/15/2016	3325649	1/3/2024	United Kingdom	NanoString Technologies, Inc.; The Board of Regents of the University of Texas System
SIMULTANEOUS QUANTIFICATION OF A PLURALITY OF PROTEINS IN A USER-DEFINED REGION OF A CROSS-SECTIONED TISSUE[36]	16742554.5	7/15/2016	3325649	1/3/2024	Ireland	NanoString Technologies, Inc.; The Board of Regents of the University of Texas System
SIMULTANEOUS QUANTIFICATION OF A PLURALITY OF PROTEINS IN A USER-DEFINED REGION OF A CROSS-SECTIONED TISSUE[37]	16742554.5	7/15/2016	3325649	1/3/2024	Italy	NanoString Technologies, Inc.; The Board of Regents of the University of Texas System

[33] Patent is co-owned with The Board of Regents of the University of Texas System and Assignor only assigns Assignor's interest in the patent.

[34] Patent is co-owned with The Board of Regents of the University of Texas System and Assignor only assigns Assignor's interest in the patent.

[35] Patent is co-owned with The Board of Regents of the University of Texas System and Assignor only assigns Assignor's interest in the patent.

[36] Patent is co-owned with The Board of Regents of the University of Texas System and Assignor only assigns Assignor's interest in the patent.

[37] Patent is co-owned with The Board of Regents of the University of Texas System and Assignor only assigns Assignor's interest in the patent.

SIMULTANEOUS QUANTIFICATION OF A PLURALITY OF PROTEINS IN A USER-DEFINED REGION OF A CROSS-SECTIONED TISSUE[38]	2018-502120	7/15/2016	6971219	11/4/2021	Japan	NanoString Technologies, Inc.; The Board of Regents of the University of Texas System
SIMULTANEOUS QUANTIFICATION OF A PLURALITY OF PROTEINS IN A USER-DEFINED REGION OF A CROSS-SECTIONED TISSUE[39]	10-2018-7004423	7/15/2016	2545430	6/15/2023	Republic of Korea	NanoString Technologies, Inc.; The Board of Regents of the University of Texas System
SIMULTANEOUS QUANTIFICATION OF A PLURALITY OF PROTEINS IN A USER-DEFINED REGION OF A CROSS-SECTIONED TISSUE[40]	11201800412U	7/15/2016	11201800412U	7/22/2021	Singapore	NanoString Technologies, Inc.; The Board of Regents of the University of Texas System
SIMULTANEOUS QUANTIFICATION OF GENE EXPRESSION IN A USER-DEFINED REGION OF A CROSS-SECTIONED TISSUE[41]	15/211,230	7/15/2016	10,640,816	5/5/2020	United States	NanoString Technologies, Inc.; The Board of Regents of the University of Texas System
SIMULTANEOUS QUANTIFICATION OF GENE EXPRESSION IN A USER-DEFINED REGION OF	16/596,596	10/8/2019	11,708,602	7/25/2023	United States	NanoString Technologies, Inc.; The Board of Regents of the

[38] Patent is co-owned with The Board of Regents of the University of Texas System and Assignor only assigns Assignor's interest in the patent.

[39] Patent is co-owned with The Board of Regents of the University of Texas System and Assignor only assigns Assignor's interest in the patent.

[40] Patent is co-owned with The Board of Regents of the University of Texas System and Assignor only assigns Assignor's interest in the patent.

[41] Terminal disclaimers exist between U.S. patent no. 10,501,777 (SIMULTANEOUS QUANTIFICATION OF A PLURALITY OF PROTEINS IN A USER-DEFINED REGION OF A CROSS-SECTIONED TISSUE) and U.S. patent no. 10,640,816 (SIMULTANEOUS QUANTIFICATION OF GENE EXPRESSION IN A USER-DEFINED REGION OF A CROSS-SECTIONED TISSUE). Patent is also co-owned with The Board of Regents of the University of Texas System and Assignor only assigns Assignor's interest in the patent.

A CROSS-SECTIONED TISSUE[42]						University of Texas System
SIMULTANEOUS QUANTIFICATION OF GENE EXPRESSION IN A USER-DEFINED REGION OF A CROSS-SECTIONED TISSUE[43]	18/331,043	6/7/2023			United States	NanoString Technologies, Inc.; The Board of Regents of the University of Texas System
SIMULTANEOUS QUANTIFICATION OF GENE EXPRESSION IN A USER-DEFINED REGION OF A CROSS-SECTIONED TISSUE[44]	2021203139	7/15/2016	2021203139	10/13/2022	Australia	NanoString Technologies, Inc.; The Board of Regents of the University of Texas System
SIMULTANEOUS QUANTIFICATION OF GENE EXPRESSION IN A USER-DEFINED REGION OF A CROSS-SECTIONED TISSUE[45]	202110942183.9	7/15/2016			China	NanoString Technologies, Inc.; The Board of Regents of the University of Texas System
SIMULTANEOUS QUANTIFICATION OF GENE EXPRESSION IN A USER-DEFINED REGION OF A CROSS-SECTIONED TISSUE	24150046.1	7/15/2016			European Patent Office	NanoString Technologies, Inc.
SIMULTANEOUS QUANTIFICATION OF GENE EXPRESSION IN A USER-DEFINED REGION OF	2021-178580	7/15/2016			Japan	NanoString Technologies, Inc.; The Board of Regents of the University of Texas System

[42] Patent is co-owned with The Board of Regents of the University of Texas System and Assignor only assigns Assignor's interest in the patent.

[43] Patent is co-owned with The Board of Regents of the University of Texas System and Assignor only assigns Assignor's interest in the patent.

[44] Patent is co-owned with The Board of Regents of the University of Texas System and Assignor only assigns Assignor's interest in the patent.

[45] Patent is co-owned with The Board of Regents of the University of Texas System and Assignor only assigns Assignor's interest in the patent.

A CROSS-SECTIONED TISSUE[46]						
SIMULTANEOUS QUANTIFICATION OF GENE EXPRESSION IN A USER-DEFINED REGION OF A CROSS-SECTIONED TISSUE[47]	10202107053Q	7/15/2016			Singapore	NanoString Technologies, Inc.; The Board of Regents of the University of Texas System
SIMULTANEOUS QUANTIFICATION OF GENE EXPRESSION IN A USER-DEFINED REGION OF A CROSS-SECTIONED TISSUE[48]	2016295158	7/15/2016	2016295158	6/10/2021	Australia	NanoString Technologies, Inc.; The Board of Regents of the University of Texas System
SIMULTANEOUS QUANTIFICATION OF GENE EXPRESSION IN A USER-DEFINED REGION OF A CROSS-SECTIONED TISSUE[49]	2992492	7/15/2016			Canada	NanoString Technologies, Inc.; The Board of Regents of the University of Texas System
SIMULTANEOUS QUANTIFICATION OF GENE EXPRESSION IN A USER-DEFINED REGION OF A CROSS-SECTIONED TISSUE	16742557.8	7/15/2016	3325650	1/3/2024	Switzerland	NanoString Technologies, Inc.
SIMULTANEOUS QUANTIFICATION OF GENE EXPRESSION IN A USER-DEFINED REGION OF	201680054038.4	7/15/2016	ZL201680054038.4	9/3/2021	China	NanoString Technologies, Inc.; The Board of Regents of the University of Texas System

[46] Patent is co-owned with The Board of Regents of the University of Texas System and Assignor only assigns Assignor's interest in the patent.

[47] Patent is co-owned with The Board of Regents of the University of Texas System and Assignor only assigns Assignor's interest in the patent.

[48] Patent is co-owned with The Board of Regents of the University of Texas System and Assignor only assigns Assignor's interest in the patent.

[49] Patent is co-owned with The Board of Regents of the University of Texas System and Assignor only assigns Assignor's interest in the patent.

A CROSS-SECTIONED TISSUE[50]						
SIMULTANEOUS QUANTIFICATION OF GENE EXPRESSION IN A USER-DEFINED REGION OF A CROSS-SECTIONED TISSUE	16742557.8	7/15/2016	3325650	1/3/2024	Germany	NanoString Technologies, Inc.
SIMULTANEOUS QUANTIFICATION OF GENE EXPRESSION IN A USER-DEFINED REGION OF A CROSS-SECTIONED TISSUE[51]	16742557.8	7/15/2016	3325650	1/3/2024	European Patent Office	NanoString Technologies, Inc.; The Board of Regents of the University of Texas System
SIMULTANEOUS QUANTIFICATION OF GENE EXPRESSION IN A USER-DEFINED REGION OF A CROSS-SECTIONED TISSUE	16742557.8	7/15/2016	3325650	1/3/2024	Spain	NanoString Technologies, Inc.
SIMULTANEOUS QUANTIFICATION OF GENE EXPRESSION IN A USER-DEFINED REGION OF A CROSS-SECTIONED TISSUE	16742557.8	7/15/2016	3325650	1/3/2024	France	NanoString Technologies, Inc.
SIMULTANEOUS QUANTIFICATION OF GENE EXPRESSION IN A USER-DEFINED REGION OF A CROSS-SECTIONED TISSUE	16742557.8	7/15/2016	3325650	1/3/2024	United Kingdom	NanoString Technologies, Inc.
SIMULTANEOUS QUANTIFICATION OF GENE EXPRESSION IN A USER-DEFINED REGION OF A CROSS-SECTIONED TISSUE	16742557.8	7/15/2016	3325650	1/3/2024	Ireland	NanoString Technologies, Inc.

[50] Patent is co-owned with The Board of Regents of the University of Texas System and Assignor only assigns Assignor's interest in the patent.

[51] Patent is co-owned with The Board of Regents of the University of Texas System and Assignor only assigns Assignor's interest in the patent.

SIMULTANEOUS QUANTIFICATION OF GENE EXPRESSION IN A USER-DEFINED REGION OF A CROSS-SECTIONED TISSUE	16742557.8	7/15/2016	3325650	1/3/2024	Italy	NanoString Technologies, Inc.
SIMULTANEOUS QUANTIFICATION OF GENE EXPRESSION IN A USER-DEFINED REGION OF A CROSS-SECTIONED TISSUE[52]	2018-502114	7/15/2016	6971218	11/4/2021	Japan	NanoString Technologies, Inc.; The Board of Regents of the University of Texas System
SIMULTANEOUS QUANTIFICATION OF GENE EXPRESSION IN A USER-DEFINED REGION OF A CROSS-SECTIONED TISSUE[53]	10-2018-7004425	7/15/2016	1026086530000	11/28/2023	Republic of Korea	NanoString Technologies, Inc.; The Board of Regents of the University of Texas System
SIMULTANEOUS QUANTIFICATION OF GENE EXPRESSION IN A USER-DEFINED REGION OF A CROSS-SECTIONED TISSUE[54]	11201800435V	7/15/2016	11201800435V	7/21/2021	Singapore	NanoString Technologies, Inc.; The Board of Regents of the University of Texas System
DESIGNS FOR FLUORESCENT NUCLEIC ACID PROBE DETECTION CARTRIDGE	29/539,294	9/11/2015	D787,700	5/23/2017	United States	NanoString Technologies, Inc.
CHEMICAL COMPOSITIONS AND USES THEREOF	17/688,174	3/7/2022			United States	NanoString Technologies, Inc.
METHODS FOR DETECTING TARGET NUCLEIC ACIDS IN A SAMPLE	202211727492.5	5/16/2017			China	NanoString Technologies, Inc.
METHODS FOR DETECTING TARGET	23183318.7	5/16/2017			Europe	NanoString Technologies, Inc.

[52] Patent is co-owned with The Board of Regents of the University of Texas System and Assignor only assigns Assignor's interest in the patent.

[53] Patent is co-owned with The Board of Regents of the University of Texas System and Assignor only assigns Assignor's interest in the patent.

[54] Patent is co-owned with The Board of Regents of the University of Texas System and Assignor only assigns Assignor's interest in the patent.

NUCLEIC ACIDS IN A SAMPLE						
METHODS FOR DETECTING TARGET NUCLEIC ACIDS IN A SAMPLE	2022-089840	5/16/2017			Japan	NanoString Technologies, Inc.
METHODS FOR DETECTING TARGET NUCLEIC ACIDS IN A SAMPLE	2017268257	5/16/2017	2017268257	12/21/2023	Australia	NanoString Technologies, Inc.
METHODS FOR DETECTING TARGET NUCLEIC ACIDS IN A SAMPLE	3023566	5/16/2017			Canada	NanoString Technologies, Inc.
METHODS FOR DETECTING TARGET NUCLEIC ACIDS IN A SAMPLE	17726083.3	5/16/2017	3458601	7/5/2023	Switzerland	NanoString Technologies, Inc.
METHODS FOR DETECTING TARGET NUCLEIC ACIDS IN A SAMPLE	201780043954.2	5/16/2017	ZL201780043954.2	1/6/2023	China	NanoString Technologies, Inc.
METHODS FOR DETECTING TARGET NUCLEIC ACIDS IN A SAMPLE	17726083.3	5/16/2017	3458601	7/5/2023	Germany	NanoString Technologies, Inc.
METHODS FOR DETECTING TARGET NUCLEIC ACIDS IN A SAMPLE	17726083.3	5/16/2017	3458601	7/5/2023	European Patent Office	NanoString Technologies, Inc.
METHODS FOR DETECTING TARGET NUCLEIC ACIDS IN A SAMPLE	17726083.3	5/16/2017	3458601	7/5/2023	Spain	NanoString Technologies, Inc.
METHODS FOR DETECTING TARGET NUCLEIC ACIDS IN A SAMPLE	17726083.3	5/16/2017	3458601	7/5/2023	France	NanoString Technologies, Inc.
METHODS FOR DETECTING TARGET NUCLEIC ACIDS IN A SAMPLE	17726083.3	5/16/2017	3458601	7/5/2023	United Kingdom	NanoString Technologies, Inc.
METHODS FOR DETECTING TARGET NUCLEIC ACIDS IN A SAMPLE	17726083.3	5/16/2017	3458601	7/5/2023	Ireland	NanoString Technologies, Inc.
METHODS FOR DETECTING TARGET NUCLEIC ACIDS IN A SAMPLE	17726083.3	5/16/2017	3458601	7/5/2023	Italy	NanoString Technologies, Inc.
METHODS FOR DETECTING TARGET NUCLEIC ACIDS IN A SAMPLE	2018-560101	5/16/2017			Japan	NanoString Technologies, Inc.
METHODS FOR DETECTING TARGET	10-2018-7036460	5/16/2017	10-2490693	1/17/2023	Republic of Korea	NanoString Technologies, Inc.

NUCLEIC ACIDS IN A SAMPLE						
METHODS FOR DETECTING TARGET NUCLEIC ACIDS IN A SAMPLE	11201809913P	5/16/2017			Singapore	NanoString Technologies, Inc.
CHEMICAL COMPOSITIONS AND METHODS OF USING SAME	15/819,151	11/21/2017	10,415,080	9/17/2019	United States	NanoString Technologies, Inc.
CHEMICAL COMPOSITIONS AND METHODS OF USING SAME	16/559,755	9/4/2019	11,279,969	3/22/2022	United States	NanoString Technologies, Inc.
CHEMICAL COMPOSITIONS AND METHODS OF USING SAME[55]	18/179,684	3/7/2023	11,821,026	11/21/2023	United States	NanoString Technologies, Inc.
CHEMICAL COMPOSITIONS AND METHODS OF USING SAME	2020210277	11/21/2017	2020210277	10/12/2023	Australia	NanoString Technologies, Inc.
CHEMICAL COMPOSITIONS AND METHODS OF USING SAME	202310011990.8	11/21/2017			China	NanoString Technologies, Inc.
CHEMICAL COMPOSITIONS AND METHODS OF USING SAME	2020-115005	11/21/2017	7137595	9/6/2022	Japan	NanoString Technologies, Inc.
CHEMICAL COMPOSITIONS AND METHODS OF USING SAME	10-2020-7034479	11/21/2017	2313431	10/8/2021	Republic of Korea	NanoString Technologies, Inc.
CHEMICAL COMPOSITIONS AND METHODS OF USING SAME	10202100951S	11/21/2017			Singapore	NanoString Technologies, Inc.
CHEMICAL COMPOSITIONS AND METHODS OF USING SAME	17/699,849	3/21/2022			United States	NanoString Technologies, Inc.
CHEMICAL COMPOSITIONS AND METHODS OF USING SAME	2023226700	11/21/2017			Australia	NanoString Technologies, Inc.
CHEMICAL COMPOSITIONS AND METHODS OF USING SAME	JP2022-136803	11/21/2017			Japan	NanoString Technologies, Inc.
CHEMICAL COMPOSITIONS AND METHODS OF USING SAME	10-2021-7032539	11/21/2017	2476709	12/7/2022	Republic of Korea	NanoString Technologies, Inc.
(Track One) CHEMICAL COMPOSITIONS AND METHODS OF USING SAME	18/471,447	9/21/2023			United States of America	NanoString Technologies, Inc.
CHEMICAL COMPOSITIONS AND METHODS OF USING SAME	10-2022-7042875	11/21/2017			Republic of Korea	NanoString Technologies, Inc.

[55] Terminal disclaimers exist between U.S. patent no. 11,821,026 (CHEMICAL COMPOSITIONS AND METHODS OF USING SAME) and U.S. patent no. 11,549,139 (CHEMICAL COMPOSITIONS AND METHODS OF USING SAME).

CHEMICAL COMPOSITIONS AND METHODS OF USING SAME	2017361521	11/21/2017	2017361521	12/10/2020	Australia	NanoString Technologies, Inc.
CHEMICAL COMPOSITIONS AND METHODS OF USING SAME	3043489	11/21/2017			Canada	NanoString Technologies, Inc.
CHEMICAL COMPOSITIONS AND METHODS OF USING SAME	201780084155.X	11/21/2017	ZL201780084155.X	1/6/2023	China	NanoString Technologies, Inc.
CHEMICAL COMPOSITIONS AND METHODS OF USING SAME	17812161.2	11/21/2017			European Patent Office	NanoString Technologies, Inc.
CHEMICAL COMPOSITIONS AND METHODS OF USING SAME	62020003792.2	11/21/2017			Hong Kong	NanoString Technologies, Inc.
CHEMICAL COMPOSITIONS AND METHODS OF USING SAME	2019-527254	11/21/2017	6730525	7/6/2020	Japan	NanoString Technologies, Inc.
CHEMICAL COMPOSITIONS AND METHODS OF USING SAME	10-2019-7017827	11/21/2017	2187291	11/30/2020	Republic of Korea	NanoString Technologies, Inc.
CHEMICAL COMPOSITIONS AND METHODS OF USING SAME	11201904263V	11/21/2017	11201904263V	2/23/2021	Singapore	NanoString Technologies, Inc.
MOLECULAR GENE SIGNATURES AND METHODS OF USING SAME	2019275404	5/20/2019			Australia	NanoString Technologies, Inc.
MOLECULAR GENE SIGNATURES AND METHODS OF USING SAME	3100200	5/20/2019			Canada	NanoString Technologies, Inc.
MOLECULAR GENE SIGNATURES AND METHODS OF USING SAME	201980048546.5	5/20/2019			China	NanoString Technologies, Inc.
MOLECULAR GENE SIGNATURES AND METHODS OF USING SAME	19732785.1	5/20/2019			European Patent Office	NanoString Technologies, Inc.
MOLECULAR GENE SIGNATURES AND METHODS OF USING SAME	62021039297.8	5/20/2019			Hong Kong	NanoString Technologies, Inc.
MOLECULAR GENE SIGNATURES AND METHODS OF USING SAME	2020-564841[56]	5/20/2019			Japan	NanoString Technologies, Inc.
MOLECULAR GENE SIGNATURES AND METHODS OF USING SAME	17/054,204	5/20/2019			United States	NanoString Technologies, Inc.
CHEMICAL COMPOSITIONS AND USES THEREOF	17/476,707	9/16/2021	11,377,689	7/5/2022	United States	NanoString Technologies, Inc.
CHEMICAL COMPOSITIONS AND USES THEREOF	17/476,712	9/16/2021	11,473,142	10/18/2022	United States	NanoString Technologies, Inc.

[56] This patent application is abandoned, but the Company filed a divisional application (JP app. no. 2024-034926).

BIOMOLECULAR PROBES AND METHODS OF DETECTING GENE AND PROTEIN EXPRESSION	17/705,580	3/28/2022			United States	NanoString Technologies, Inc.
BIOMOLECULAR PROBES AND METHODS OF DETECTING GENE AND PROTEIN EXPRESSION	10202400253P	2/11/2019			Singapore	NanoString Technologies, Inc.
BIOMOLECULAR PROBES AND METHODS OF DETECTING GENE AND PROTEIN EXPRESSION	2019216973	2/11/2019			Australia	NanoString Technologies, Inc.
BIOMOLECULAR PROBES AND METHODS OF DETECTING GENE AND PROTEIN EXPRESSION	3090699	2/11/2019			Canada	NanoString Technologies, Inc.
BIOMOLECULAR PROBES AND METHODS OF DETECTING GENE AND PROTEIN EXPRESSION	201980025119.5	2/11/2019			China	NanoString Technologies, Inc.
BIOMOLECULAR PROBES AND METHODS OF DETECTING GENE AND PROTEIN EXPRESSION	19707566.6	2/11/2019			European Patent Office	NanoString Technologies, Inc.
BIOMOLECULAR PROBES AND METHODS OF DETECTING GENE AND PROTEIN EXPRESSION	62021031693.6	2/11/2019			Hong Kong	NanoString Technologies, Inc.
BIOMOLECULAR PROBES AND METHODS OF DETECTING GENE AND PROTEIN EXPRESSION	2020-542878	2/11/2019	7372927	10/24/2023	Japan	NanoString Technologies, Inc.
BIOMOLECULAR PROBES AND METHODS OF DETECTING GENE AND PROTEIN EXPRESSION	10-2020-7026382	2/11/2019			Republic of Korea	NanoString Technologies, Inc.
BIOMOLECULAR PROBES AND METHODS OF DETECTING GENE AND PROTEIN EXPRESSION	11202007501S	2/11/2019			Singapore	NanoString Technologies, Inc.
GENE EXPRESSION ASSAY FOR MEASUREMENT OF DNA MISMATCH REPAIR DEFICIENCY	17/086,842	11/2/2020			United States	NanoString Technologies, Inc.
CHEMICAL COMPOSITIONS AND METHODS OF USING SAME[57]	16/411,394	5/14/2019	11,549,139	1/10/2023	United States	NanoString Technologies, Inc.

[57] Terminal disclaimers exist between U.S. patent no. 11,821,026 (CHEMICAL COMPOSITIONS AND METHODS OF USING SAME) and U.S. patent no. 11,549,139 (CHEMICAL COMPOSITIONS AND METHODS OF USING SAME).

CHEMICAL COMPOSITIONS AND METHODS OF USING SAME	18/069,565	12/21/2022			United States	NanoString Technologies, Inc.
CHEMICAL COMPOSITIONS AND METHODS OF USING SAME	2019271028	5/14/2019			Australia	NanoString Technologies, Inc.
CHEMICAL COMPOSITIONS AND METHODS OF USING SAME	3099909	5/14/2019			Canada	NanoString Technologies, Inc.
CHEMICAL COMPOSITIONS AND METHODS OF USING SAME	201980047067.1	5/14/2019			China	NanoString Technologies, Inc.
CHEMICAL COMPOSITIONS AND METHODS OF USING SAME	19732767.9	5/14/2019			European Patent Office	NanoString Technologies, Inc.
CHEMICAL COMPOSITIONS AND METHODS OF USING SAME	62021037831.6	5/14/2019			Hong Kong	NanoString Technologies, Inc.
CHEMICAL COMPOSITIONS AND METHODS OF USING SAME	2020-564214	5/14/2019			Japan	NanoString Technologies, Inc.
CHEMICAL COMPOSITIONS AND METHODS OF USING SAME	10-2020-7035491	5/14/2019			Republic of Korea	NanoString Technologies, Inc.
CHEMICAL COMPOSITIONS AND METHODS OF USING SAME	11202011274Y	5/14/2019			Singapore	NanoString Technologies, Inc.
METHODS, APPARATUSES, SYSTEMS AND DEVICES FOR MOBILE DIGITAL SPATIAL PROFILING OF PATHOLOGICAL SPECIMENS	2019406198	12/20/2019			Australia	NanoString Technologies, Inc.
METHODS, APPARATUSES, SYSTEMS AND DEVICES FOR MOBILE DIGITAL SPATIAL PROFILING OF PATHOLOGICAL SPECIMENS	3123868	12/20/2019			Canada	NanoString Technologies, Inc.
METHODS, APPARATUSES, SYSTEMS AND DEVICES FOR MOBILE DIGITAL SPATIAL PROFILING OF PATHOLOGICAL SPECIMENS	201980092712.1	12/20/2019			China	NanoString Technologies, Inc.
METHODS, APPARATUSES, SYSTEMS AND DEVICES FOR MOBILE DIGITAL SPATIAL PROFILING OF PATHOLOGICAL SPECIMENS	19897716.7	12/20/2019			European Patent Office	NanoString Technologies, Inc.
METHODS, APPARATUSES, SYSTEMS AND DEVICES FOR MOBILE DIGITAL SPATIAL PROFILING OF	62022051762.2	12/20/2019			Hong Kong	NanoString Technologies, Inc.

PATHOLOGICAL SPECIMENS						
METHODS, APPARATUSES, SYSTEMS AND DEVICES FOR MOBILE DIGITAL SPATIAL PROFILING OF PATHOLOGICAL SPECIMENS	2021-535867	12/20/2019			Japan	NanoString Technologies, Inc.
METHODS, APPARATUSES, SYSTEMS AND DEVICES FOR MOBILE DIGITAL SPATIAL PROFILING OF PATHOLOGICAL SPECIMENS	10-2021-7022328	12/20/2019			Republic of Korea	NanoString Technologies, Inc.
METHODS, APPARATUSES, SYSTEMS AND DEVICES FOR MOBILE DIGITAL SPATIAL PROFILING OF PATHOLOGICAL SPECIMENS	11202106723T	12/20/2019			Singapore	NanoString Technologies, Inc.
METHODS, APPARATUSES, SYSTEMS AND DEVICES FOR MOBILE DIGITAL SPATIAL PROFILING OF PATHOLOGICAL SPECIMENS	17/413,674	12/20/2019			United States	NanoString Technologies, Inc.
SYSTEMS AND METHODS FOR SPATIAL MAPPING OF EXPRESSION PROFILING	2020365118	10/16/2020			Australia	NanoString Technologies, Inc.
SYSTEMS AND METHODS FOR SPATIAL MAPPING OF EXPRESSION PROFILING	3153886	10/16/2020			Canada	NanoString Technologies, Inc.
SYSTEMS AND METHODS FOR SPATIAL MAPPING OF EXPRESSION PROFILING	202080087788.8	10/16/2020			China	NanoString Technologies, Inc.
SYSTEMS AND METHODS FOR SPATIAL MAPPING OF EXPRESSION PROFILING	20877296.2	10/16/2020			European Patent Office	NanoString Technologies, Inc.
SYSTEMS AND METHODS FOR SPATIAL MAPPING OF EXPRESSION PROFILING	62023068393.5	10/16/2020			Hong Kong	NanoString Technologies, Inc.
SYSTEMS AND METHODS FOR SPATIAL MAPPING OF EXPRESSION PROFILING	2022-522649	10/16/2020			Japan	NanoString Technologies, Inc.
SYSTEMS AND METHODS FOR SPATIAL MAPPING OF EXPRESSION PROFILING	10-2022-7015238	10/16/2020			Republic of Korea	NanoString Technologies, Inc.
SYSTEMS AND METHODS FOR SPATIAL MAPPING OF EXPRESSION PROFILING	11202203670V	10/16/2020			Singapore	NanoString Technologies, Inc.
SYSTEMS AND METHODS FOR SPATIAL MAPPING OF EXPRESSION PROFILING	17/768,625	10/16/2020			United States	NanoString Technologies, Inc.

BIOASSAY SUBSTRATE HAVING FIDUCIAL DOMAINS AND METHODS OF MANUFACTURE THEREOF	17/996,887	4/23/2021			United States	NanoString Technologies, Inc./LAM Research Corporation
COMPOSITIONS AND METHODS FOR IN SITU SINGLE CELL ANALYSIS USING ENZYMATIC NUCLEIC ACID EXTENSION	2021293238	6/17/2021			Australia	NanoString Technologies, Inc.
COMPOSITIONS AND METHODS FOR IN SITU SINGLE CELL ANALYSIS USING ENZYMATIC NUCLEIC ACID EXTENSION	3,183,217	6/17/2021			Canada	NanoString Technologies, Inc.
COMPOSITIONS AND METHODS FOR IN SITU SINGLE CELL ANALYSIS USING ENZYMATIC NUCLEIC ACID EXTENSION	202180050660.9	6/17/2021			China	NanoString Technologies, Inc.
COMPOSITIONS AND METHODS FOR IN SITU SINGLE CELL ANALYSIS USING ENZYMATIC NUCLEIC ACID EXTENSION	21740355.9	6/17/2021			European Patent Office	NanoString Technologies, Inc.
COMPOSITIONS AND METHODS FOR IN SITU SINGLE CELL ANALYSIS USING ENZYMATIC NUCLEIC ACID EXTENSION	62023073077.7	6/17/2021			Hong Kong	NanoString Technologies, Inc.
COMPOSITIONS AND METHODS FOR IN SITU SINGLE CELL ANALYSIS USING ENZYMATIC NUCLEIC ACID EXTENSION	2022-578732	6/17/2021			Japan	NanoString Technologies, Inc.
COMPOSITIONS AND METHODS FOR IN SITU SINGLE CELL ANALYSIS USING ENZYMATIC NUCLEIC ACID EXTENSION	18/010,873	6/17/2021			United States	NanoString Technologies, Inc.
CHEMICAL COMPOSITIONS AND METHODS OF USING THE SAME	2021343471	9/16/2021			Australia	NanoString Technologies, Inc.
CHEMICAL COMPOSITIONS AND METHODS OF USING THE SAME	3192943	9/16/2021			Canada	NanoString Technologies, Inc.

CHEMICAL COMPOSITIONS AND METHODS OF USING THE SAME	202180076906.X	9/16/2021			China	NanoString Technologies, Inc.
CHEMICAL COMPOSITIONS AND METHODS OF USING THE SAME	21787265.4	9/16/2021			European Patent Office	NanoString Technologies, Inc.
CHEMICAL COMPOSITIONS AND METHODS OF USING THE SAME	62024085470.8	9/16/2021			Hong Kong	NanoString Technologies, Inc.
CHEMICAL COMPOSITIONS AND METHODS OF USING THE SAME	2023-517348	9/16/2021			Japan	NanoString Technologies, Inc.
CHEMICAL COMPOSITIONS AND METHODS OF USING THE SAME	11202302027X	9/16/2021			Singapore	NanoString Technologies, Inc.
CHEMICAL COMPOSITIONS AND METHODS OF USING THE SAME	18/245,589	9/16/2021			United States	NanoString Technologies, Inc.
METHODS, SYSTEMS AND DEVICES FOR PROCESSING SEQUENCE DATA	2021359002	10/8/2021			Australia	NanoString Technologies, Inc.
METHODS, SYSTEMS AND DEVICES FOR PROCESSING SEQUENCE DATA	3195255	10/8/2021			Canada	NanoString Technologies, Inc.
METHODS, SYSTEMS AND DEVICES FOR PROCESSING SEQUENCE DATA	202180082493.60	10/8/2021			China	NanoString Technologies, Inc.
METHODS, SYSTEMS AND DEVICES FOR PROCESSING SEQUENCE DATA	21802495.8	10/8/2021			European Patent Office	NanoString Technologies, Inc.
METHODS, SYSTEMS AND DEVICES FOR PROCESSING SEQUENCE DATA	62024086405.3	10/8/2021			Hong Kong	NanoString Technologies, Inc.
METHODS, SYSTEMS AND DEVICES FOR PROCESSING SEQUENCE DATA	2023-521627	10/8/2021			Japan	NanoString Technologies, Inc.
METHODS, SYSTEMS AND DEVICES FOR PROCESSING SEQUENCE DATA	10-2023-7015424	10/8/2021			Republic of Korea	NanoString Technologies, Inc.
METHODS, SYSTEMS AND DEVICES FOR PROCESSING SEQUENCE DATA	11202302705P	10/8/2021			Singapore	NanoString Technologies, Inc.
METHODS, SYSTEMS AND DEVICES FOR PROCESSING SEQUENCE DATA	18/030,889	10/8/2021			United States	NanoString Technologies, Inc.

METHODS, SYSTEMS AND APPARATUS FOR A MULTI-SPECTRAL STRUCTURED ILLUMINATION MICROSCOPE	18/686,012	8/30/2022			United States of America	NanoString Technologies, Inc.
COMPOSITIONS AND METHODS FOR IN SITU SINGLE CELL ANALYSIS USING ENZYMATIC NUCLEIC ACID EXTENSION	22741913.2	6/17/2022			European Patent Office	NanoString Technologies, Inc.
COMPOSITIONS AND METHODS FOR IN SITU SINGLE CELL ANALYSIS USING ENZYMATIC NUCLEIC ACID EXTENSION	18/570,190	6/17/2022			United States of America	NanoString Technologies, Inc.
METHODS OF PURIFYING ANTIBODY-NUCLEIC ACID CONJUGATES	PCT/US2023/020105	4/27/2023			Patent Cooperation Treaty	NanoString Technologies, Inc.
ANALYSIS OF ASSOCIATED WITH SINGLE CELLS USING NUCLEIC ACID BARCODES	14/586,857	12/30/2014	9,580,736	2/28/2017	United States	NanoString Technologies, Inc.
ANALYSIS OF NUCLEIC ACIDS ASSOCIATED WITH SINGLE CELLS USING NUCLEIC ACID BARCODES	15/428,064	2/8/2017	10,316,345	6/11/2019	United States	NanoString Technologies, Inc.
ANALYSIS OF NUCLEIC ACIDS ASSOCIATED WITH SINGLE CELLS USING NUCLEIC ACID BARCODES	16/402,626	5/3/2019			United States	NanoString Technologies, Inc.
ANALYSIS OF NUCLEIC ACIDS ASSOCIATED WITH SINGLE CELLS USING NUCLEIC ACID BARCODES	17/842,966	6/17/2022			United States	NanoString Technologies, Inc.
ANALYSIS OF NUCLEIC ACIDS ASSOCIATED WITH SINGLE CELLS USING NUCLEIC ACID BARCODES	17/842,968	6/17/2022			United States	NanoString Technologies, Inc.
ANALYSIS OF NUCLEIC ACIDS ASSOCIATED WITH SINGLE CELLS USING NUCLEIC ACID BARCODES	18/435,438	2/7/2024			United States of America	NanoString Technologies, Inc.
ANALYSIS OF NUCLEIC ACIDS ASSOCIATED WITH SINGLE CELLS USING NUCLEIC ACID BARCODES	202111683991.4	12/30/2014			China	NanoString Technologies, Inc.

ANALYSIS OF NUCLEIC ACIDS ASSOCIATED WITH SINGLE CELLS USING NUCLEIC ACID BARCODES	22165189.6	12/30/2014			European Patent Office	NanoString Technologies, Inc.
ANALYSIS OF NUCLEIC ACIDS ASSOCIATED WITH SINGLE CELLS USING NUCLEIC ACID BARCODES	10201807112X	12/30/2014			Singapore	NanoString Technologies, Inc.
ANALYSIS OF NUCLEIC ACIDS ASSOCIATED WITH SINGLE CELLS USING NUCLEIC ACID BARCODES	14830928.9	12/30/2014	3089822	4/6/2022	Austria	NanoString Technologies, Inc.
ANALYSIS OF NUCLEIC ACIDS ASSOCIATED WITH SINGLE CELLS USING NUCLEIC ACID BARCODES	2014373757	12/30/2014	2014373757	3/26/2020	Australia	NanoString Technologies, Inc.
ANALYSIS OF NUCLEIC ACIDS ASSOCIATED WITH SINGLE CELLS USING NUCLEIC ACID BARCODES	14830928.9	12/30/2014	3089822	4/6/2022	Belgium	NanoString Technologies, Inc.
ANALYSIS OF NUCLEIC ACIDS ASSOCIATED WITH SINGLE CELLS USING NUCLEIC ACID BARCODES	2935122	12/30/2014	2935122	9/19/2023	Canada	NanoString Technologies, Inc.
ANALYSIS OF NUCLEIC ACIDS ASSOCIATED WITH SINGLE CELLS USING NUCLEIC ACID BARCODES	14830928.9	12/30/2014	3089822	4/6/2022	Switzerland	NanoString Technologies, Inc.
ANALYSIS OF NUCLEIC ACIDS ASSOCIATED WITH SINGLE CELLS USING NUCLEIC ACID BARCODES	201480076617	12/30/2014	106460033	12/24/2021	China	NanoString Technologies, Inc.
ANALYSIS OF NUCLEIC ACIDS ASSOCIATED WITH SINGLE CELLS USING NUCLEIC ACID BARCODES	14830928.9	12/30/2014	3089822	4/6/2022	Germany	NanoString Technologies, Inc.
ANALYSIS OF NUCLEIC ACIDS ASSOCIATED WITH SINGLE CELLS USING NUCLEIC ACID BARCODES	14830928.9	12/30/2014	3089822	4/6/2022	Denmark	NanoString Technologies, Inc.
ANALYSIS OF NUCLEIC ACIDS ASSOCIATED WITH SINGLE CELLS USING NUCLEIC ACID BARCODES	14830928.9	12/30/2014	3089822	4/6/2022	European Patent Office	NanoString Technologies, Inc.
ANALYSIS OF NUCLEIC ACIDS ASSOCIATED WITH SINGLE CELLS USING NUCLEIC ACID BARCODES	14830928.9	12/30/2014	3089822	4/6/2022	Spain	NanoString Technologies, Inc.
ANALYSIS OF NUCLEIC ACIDS ASSOCIATED WITH SINGLE CELLS USING NUCLEIC ACID BARCODES	14830928.9	12/30/2014	3089822	4/6/2022	France	NanoString Technologies, Inc.
ANALYSIS OF NUCLEIC ACIDS ASSOCIATED WITH SINGLE CELLS USING NUCLEIC ACID BARCODES	14830928.9	12/30/2014	3089822	4/6/2022	United Kingdom	NanoString Technologies, Inc.

ANALYSIS OF NUCLEIC ACIDS ASSOCIATED WITH SINGLE CELLS USING NUCLEIC ACID BARCODES	17101107.9	12/30/2014	1227354	11/25/2022	Hong Kong	NanoString Technologies, Inc.
ANALYSIS OF NUCLEIC ACIDS ASSOCIATED WITH SINGLE CELLS USING NUCLEIC ACID BARCODES	14830928.9	12/30/2014	3089822	4/6/2022	Ireland	NanoString Technologies, Inc.
ANALYSIS OF NUCLEIC ACIDS ASSOCIATED WITH SINGLE CELLS USING NUCLEIC ACID BARCODES	14830928.9	12/30/2014	3089822	4/6/2022	Italy	NanoString Technologies, Inc.
ANALYSIS OF NUCLEIC ACIDS ASSOCIATED WITH SINGLE CELLS USING NUCLEIC ACID BARCODES	2016-544526	12/30/2014	6608368	11/1/2019	Japan	NanoString Technologies, Inc.
ANALYSIS OF NUCLEIC ACIDS ASSOCIATED WITH SINGLE CELLS USING NUCLEIC ACID BARCODES	10-2016-7020514	12/30/2014	10-2433825	8/12/2022	Republic of Korea	NanoString Technologies, Inc.
ANALYSIS OF NUCLEIC ACIDS ASSOCIATED WITH SINGLE CELLS USING NUCLEIC ACID BARCODES	14830928.9	12/30/2014	3089822	4/6/2022	Poland	NanoString Technologies, Inc.
ANALYSIS OF NUCLEIC ACIDS ASSOCIATED WITH SINGLE CELLS USING NUCLEIC ACID BARCODES	14830928.9	12/30/2014	3089822	4/6/2022	Portugal	NanoString Technologies, Inc.
ANALYSIS OF NUCLEIC ACIDS ASSOCIATED WITH SINGLE CELLS USING NUCLEIC ACID BARCODES	11201605344Y	12/30/2014	11201605344Y	8/27/2018	Singapore	NanoString Technologies, Inc.
ASSAY FOR RECOMBINASE ACCESSIBLE CHROMATIN AND RELATED COMPOSITIONS AND METHODS	63/490,865	3/17/2023			United States	NanoString Technologies, Inc.
ASSAY FOR RECOMBINASE ACCESSIBLE CHROMATIN AND RELATED COMPOSITIONS AND METHODS	63/490,868	3/17/2023			United States	NanoString Technologies, Inc.
ASSAY FOR RECOMBINASE ACCESSIBLE CHROMATIN AND RELATED COMPOSITIONS AND METHODS	63/490,871	3/17/2023			United States	NanoString Technologies, Inc.
ASSAY FOR RECOMBINASE ACCESSIBLE CHROMATIN AND RELATED COMPOSITIONS AND METHODS	63/490,873	3/17/2023			United States	NanoString Technologies, Inc.

ASSAY FOR RECOMBINASE ACCESSIBLE CHROMATIN AND RELATED COMPOSITIONS AND METHODS	PCT/US2024/020154	3/15/2024			United States of America	NanoString Technologies, Inc.
NUCLEIC ACID PROBES FOR COMBINED SEQUENCING AND SPATIAL ANALYSIS	63/490,858	3/17/2023			United States	NanoString Technologies, Inc.
NUCLEIC ACID PROBES FOR COMBINED SEQUENCING AND SPATIAL ANALYSIS	63/490,860	3/17/2023			United States	NanoString Technologies, Inc.
NUCLEIC ACID PROBES FOR COMBINED SEQUENCING AND SPATIAL ANALYSIS	PCT/US2024/020073	3/15/2024			United States of America	NanoString Technologies, Inc.
METHODS FOR DETECTING TARGET NUCLEIC ACIDS IN A SAMPLE	63/582,663	9/14/2023			United States	NanoString Technologies, Inc.
METHODS FOR DETECTING TARGET NUCLEIC ACIDS IN A SAMPLE	63/582,665	9/14/2023			United States	NanoString Technologies, Inc.
METHODS FOR DETECTING TARGET NUCLEIC ACIDS IN A SAMPLE	63/582,668	9/14/2023			United States	NanoString Technologies, Inc.
BISPECIFC CD123 X CD3 DIABODIES FOR THE TREATMENT OF HEMATOLOGIC MALIGNANCIES[58]	2019371243	10/29/2019			Australia	NanoString Technologies, Inc.; MacroGenics, Inc.
BISPECIFC CD123 X CD3 DIABODIES FOR THE TREATMENT OF HEMATOLOGIC MALIGNANCIES[59]	112021008283-2	10/29/2019			Brazil	NanoString Technologies, Inc.; MacroGenics, Inc.
BISPECIFC CD123 X CD3 DIABODIES FOR THE TREATMENT OF	3118081	10/29/2019			Canada	NanoString Technologies, Inc.; MacroGenics, Inc.

[58] Patent is co-owned with MacroGenics, Inc. and Assignor only assigns Assignor's interest in the patent.

[59] Patent is co-owned with MacroGenics, Inc. and Assignor only assigns Assignor's interest in the patent.

HEMATOLOGIC MALIGNANCIES[60]						
BISPECIFC CD123 X CD3 DIABODIES FOR THE TREATMENT OF HEMATOLOGIC MALIGNANCIES[61]	201980087139.5	10/29/2019			China	NanoString Technologies, Inc.; MacroGenics, Inc.
BISPECIFC CD123 X CD3 DIABODIES FOR THE TREATMENT OF HEMATOLOGIC MALIGNANCIES[62]	19878838.2	10/29/2019			Europe	NanoString Technologies, Inc.; MacroGenics, Inc.
BISPECIFC CD123 X CD3 DIABODIES FOR THE TREATMENT OF HEMATOLOGIC MALIGNANCIES[63]	282827	10/29/2019			Israel	NanoString Technologies, Inc.; MacroGenics, Inc.
BISPECIFC CD123 X CD3 DIABODIES FOR THE TREATMENT OF HEMATOLOGIC MALIGNANCIES[64]	202117022877	10/29/2019			India	NanoString Technologies, Inc.; MacroGenics, Inc.
BISPECIFC CD123 X CD3 DIABODIES FOR THE TREATMENT OF HEMATOLOGIC MALIGNANCIES[65]	2021-548536	10/29/2019			Japan	NanoString Technologies, Inc.; MacroGenics, Inc.
BISPECIFC CD123 X CD3 DIABODIES FOR THE TREATMENT OF HEMATOLOGIC MALIGNANCIES[66]	10-2021-7014961	10/29/2019			Republic of Korea	NanoString Technologies, Inc.; MacroGenics, Inc.
BISPECIFC CD123 X CD3 DIABODIES FOR THE TREATMENT OF HEMATOLOGIC MALIGNANCIES[67]	MX/a/2021/004868	10/29/2019			Mexico	NanoString Technologies, Inc.; MacroGenics, Inc.

[60] Patent is co-owned with MacroGenics, Inc. and Assignor only assigns Assignor's interest in the patent.

[61] Patent is co-owned with MacroGenics, Inc. and Assignor only assigns Assignor's interest in the patent.

[62] Patent is co-owned with MacroGenics, Inc. and Assignor only assigns Assignor's interest in the patent.

[63] Patent is co-owned with MacroGenics, Inc. and Assignor only assigns Assignor's interest in the patent.

[64] Patent is co-owned with MacroGenics, Inc. and Assignor only assigns Assignor's interest in the patent.

[65] Patent is co-owned with MacroGenics, Inc. and Assignor only assigns Assignor's interest in the patent.

[66] Patent is co-owned with MacroGenics, Inc. and Assignor only assigns Assignor's interest in the patent.

[67] Patent is co-owned with MacroGenics, Inc. and Assignor only assigns Assignor's interest in the patent.

BISPECIFC CD123 X CD3 DIABODIES FOR THE TREATMENT OF HEMATOLOGIC MALIGNANCIES[68]	775494	10/29/2019			New Zealand	NanoString Technologies, Inc.; MacroGenics, Inc.
BISPECIFC CD123 X CD3 DIABODIES FOR THE TREATMENT OF HEMATOLOGIC MALIGNANCIES[69]	2021114463	10/29/2019			Russian Federation	NanoString Technologies, Inc.; MacroGenics, Inc.
BISPECIFC CD123 X CD3 DIABODIES FOR THE TREATMENT OF HEMATOLOGIC MALIGNANCIES[70]	11202104367R	10/29/2019			Singapore	NanoString Technologies, Inc.; MacroGenics, Inc.
BISPECIFC CD123 X CD3 DIABODIES FOR THE TREATMENT OF HEMATOLOGIC MALIGNANCIES[71]	17/290,061	10/29/2019			United States	NanoString Technologies, Inc.; MacroGenics, Inc.
BISPECIFC CD123 X CD3 DIABODIES FOR THE TREATMENT OF HEMATOLOGIC MALIGNANCIES[72]	2021/02775	10/29/2019	2021/02775	3/30/2022	South Africa	NanoString Technologies, Inc.; MacroGenics, Inc.; Nottingham Trent University
SYSTEMS AND METHODS FOR CELLLULAR SPATIAL ANALYSIS	63/578,444	8/24/2023			United States	NanoString Technologies, Inc.
ROBUST CELL SEGMENTATION USING HIGH-PLEX PROTEIN AND TRANSCRIPT IMAGES	63/585,842	9/27/2023			United States	NanoString Technologies, Inc.
SPATIAL BIOLOGY INFORMATICS INTERGRATION PORTAL WITH PROGRAMMABLE MACHINE LEARNING PIPELINE ORCHESTRATOR	PCT/US2023/067821	6/2/2023			Patent Cooperation Treaty	NanoString Technologies, Inc.
SYSTEMS AND METHODS UTILIZING IMPROVED DEFINITION OF CELL	PCT/US2023/084264	12/15/2023			Patent Cooperation Treaty	NanoString Technologies, Inc.

[68] Patent is co-owned with MacroGenics, Inc. and Assignor only assigns Assignor's interest in the patent.

[69] Patent is co-owned with MacroGenics, Inc. and Assignor only assigns Assignor's interest in the patent.

[70] Patent is co-owned with MacroGenics, Inc. and Assignor only assigns Assignor's interest in the patent.

[71] Patent is co-owned with MacroGenics, Inc. and Assignor only assigns Assignor's interest in the patent.

[72] Patent is co-owned with MacroGenics, Inc. and Assignor only assigns Assignor's interest in the patent.

BOUNDARIES IN BIOLOGICAL IMAGES						
METHOD AND SYSTEM OF MULTI-MODAL SUB-CELLULAR SEGMENTATION	63/507824	6/13/2023			United States	NanoString Technologies, Inc.
OBINUTUZUMAB TREATMENT OF A DLBCL PATIENT SUBGROUP	18/163,810	2/2/2023			United States	F. Hoffman-LaRoche AG And NanoString Technologies, Inc.[73]
OBINUTUZUMAB TREATMENT OF A DLBCL PATIENT SUBGROUP	16/784,021	2/6/2020	11597772	3/7/2023	United States	F. Hoffman-LaRoche AG And NanoString Technologies, Inc.[74]
OBINUTUZUMAB TREATMENT OF A DLBCL PATIENT SUBGROUP	2018-314765	8/8/2018			Australia	F. Hoffman-LaRoche AG and NanoString Technologies, Inc.[75]
OBINUTUZUMAB TREATMENT OF A DLBCL PATIENT SUBGROUP	3071618	8/8/2018			Canada	F. Hoffman-LaRoche AG and NanoString Technologies, Inc.[76]
OBINUTUZUMAB TREATMENT OF A DLBCL PATIENT SUBGROUP	111032692	8/8/2018			China	F. Hoffman-LaRoche AG and NanoString Technologies, Inc.[77]
OBINUTUZUMAB TREATMENT OF A DLBCL PATIENT SUBGROUP	20200061	8/8/2018			Costa Rica	F. Hoffman-LaRoche AG and NanoString Technologies, Inc.[78]

[73] Patent is co-owned with F. Hoffman-LaRoche AG. and Assignor only assigns Assignor's interest in the patent.

[74] Patent is co-owned with F. Hoffman-LaRoche AG. and Assignor only assigns Assignor's interest in the patent.

[75] Patent is co-owned with F. Hoffman-LaRoche AG. and Assignor only assigns Assignor's interest in the patent.

[76] Patent is co-owned with F. Hoffman-LaRoche AG. and Assignor only assigns Assignor's interest in the patent.

[77] Patent is co-owned with F. Hoffman-LaRoche AG. and Assignor only assigns Assignor's interest in the patent.

[78] Patent is co-owned with F. Hoffman-LaRoche AG. and Assignor only assigns Assignor's interest in the patent.

OBINUTUZUMAB TREATMENT OF A DLBCL PATIENT SUBGROUP	18755421.7	8/8/2018	3665196	10/19/2022	Europe	F. Hoffman-LaRoche AG and NanoString Technologies, Inc.[79]
OBINUTUZUMAB TREATMENT OF A DLBCL PATIENT SUBGROUP	18755421.7	8/8/2018	2933256	2/3/2023	Spain	F. Hoffman-LaRoche AG and NanoString Technologies, Inc.[80]
OBINUTUZUMAB TREATMENT OF A DLBCL PATIENT SUBGROUP	2020-272418				Israel	F. Hoffman-LaRoche AG and NanoString Technologies, Inc.[81]
OBINUTUZUMAB TREATMENT OF A DLBCL PATIENT SUBGROUP	2023-136335				Japan	F. Hoffman-LaRoche AG and NanoString Technologies, Inc.[82]
OBINUTUZUMAB TREATMENT OF A DLBCL PATIENT SUBGROUP	2020-505912	8/8/2018	7418322B	1/19/2024	Japan	F. Hoffman-LaRoche AG and NanoString Technologies, Inc.[83]
OBINUTUZUMAB TREATMENT OF A DLBCL PATIENT SUBGROUP	2018-49830	8/8/2018			Morocco	F. Hoffman-LaRoche AG and NanoString Technologies, Inc.[84]
OBINUTUZUMAB TREATMENT OF A DLBCL PATIENT SUBGROUP	2020001493	8/8/2018			Mexico	F. Hoffman-LaRoche AG and NanoString Technologies, Inc.[85]

[79] Patent is co-owned with F. Hoffman-LaRoche AG. and Assignor only assigns Assignor's interest in the patent.

[80] Patent is co-owned with F. Hoffman-LaRoche AG. and Assignor only assigns Assignor's interest in the patent.

[81] Patent is co-owned with F. Hoffman-LaRoche AG. and Assignor only assigns Assignor's interest in the patent.

[82] Patent is co-owned with F. Hoffman-LaRoche AG. and Assignor only assigns Assignor's interest in the patent.

[83] Patent is co-owned with F. Hoffman-LaRoche AG. and Assignor only assigns Assignor's interest in the patent.

[84] Patent is co-owned with F. Hoffman-LaRoche AG. and Assignor only assigns Assignor's interest in the patent.

[85] Patent is co-owned with F. Hoffman-LaRoche AG. and Assignor only assigns Assignor's interest in the patent.

OBINUTUZUMAB TREATMENT OF A DLBCL PATIENT SUBGROUP	2020000199	8/8/2018			Peru	F. Hoffman-LaRoche AG and NanoString Technologies, Inc.[86]
OBINUTUZUMAB TREATMENT OF A DLBCL PATIENT SUBGROUP	2018-755421	8/8/2018	3665196	01/23/2023	Poland	F. Hoffman-LaRoche AG and NanoString Technologies, Inc.[87]
OBINUTUZUMAB TREATMENT OF A DLBCL PATIENT SUBGROUP	2020-11202000985	8/8/2018			Singapore	F. Hoffman-LaRoche AG and NanoString Technologies, Inc.[88]
OBINUTUZUMAB TREATMENT OF A DLBCL PATIENT SUBGROUP	202323297	8/8/2018			Taiwan	F. Hoffman-LaRoche AG and NanoString Technologies, Inc.[89]
OBINUTUZUMAB TREATMENT OF A DLBCL PATIENT SUBGROUP	107127631	8/8/2018	I772488	8/1/2022	Taiwan	F. Hoffman-LaRoche AG and NanoString Technologies, Inc.[90]
OBINUTUZUMAB TREATMENT OF A DLBCL PATIENT SUBGROUP	202001356	8/8/2018	126204	8/31/2022	Ukraine	F. Hoffman-LaRoche AG and NanoString Technologies, Inc.[91]
MULTIVALENT PROBE WITH SINGLE NUCLEOTIDE RESOLUTION.	2018-511730[92]	9/6/2016			Japan	NanoString Technologies, Inc.

[86] Patent is co-owned with F. Hoffman-LaRoche AG. and Assignor only assigns Assignor's interest in the patent.

[87] Patent is co-owned with F. Hoffman-LaRoche AG. and Assignor only assigns Assignor's interest in the patent.

[88] Patent is co-owned with F. Hoffman-LaRoche AG. and Assignor only assigns Assignor's interest in the patent.

[89] Patent is co-owned with F. Hoffman-LaRoche AG. and Assignor only assigns Assignor's interest in the patent.

[90] Patent is co-owned with F. Hoffman-LaRoche AG. and Assignor only assigns Assignor's interest in the patent.

[91] Patent is co-owned with F. Hoffman-LaRoche AG. and Assignor only assigns Assignor's interest in the patent.

[92] The family of JPN patent no. 2018-511730 (MULTIVALENT PROBE WITH SINGLE NUCLEOTIDE RESOLUTION) was abandoned in 2019.

MULTIVALENT PROBE WITH SINGLE NUCLEOTIDE RESOLUTION.	2018-7009405[93]	9/6/2016			Republic of Korea	NanoString Technologies, Inc.
A METHOD FOR DECONVOLUTION OF MIXED CELL POPULATIONS USING GENE EXPRESSION DATA.	2017-506897[94]	8/4/2015			Japan	NanoString Technologies, Inc.
MULTIPLEXABLE TAG-BASED REPORTER SYSTEM.	2016-111996[95]	10/18/2016			Hong Kong	NanoString Technologies, Inc.
METHODS TO PREDICT RISK OF RECURRENCE IN NODE-POSITIVE EARLY BREAST CANCER.	2016-111038[96]	9/20/2016			Hong Kong	NanoString Technologies, Inc.
MULTIVARIATE DIAGNOSTIC ASSAYS AND METHODS FOR USING THE SAME.	2018-72708[97]	4/4/2018			Japan	Nanostring Technologies, Inc.
BIOMOLECULAR PROBES AND METHODS OF DETECTING GENE AND PROTEIN EXPRESSION	2023-180942	10/20/2023			Japan	NanoString Technologies, Inc.
CHEMICAL COMPOSITIONS AND METHODS OF USING SAME	2023-7012434	9/16/2021			Republic of Korea	NanoString Technologies, Inc.
METHODS FOR DETECTING TARGET NUCLEIC ACIDS IN A SAMPLE	2023278046	12/6/2023			Australia	NanoString Technologies, Inc.
METHODS AND APPARATUSES FOR GENE PURIFICATION AND IMAGING	2020-118680[98]	7/9/2020			Japan	NanoString Technologies, Inc.

[93] The family of KR patent no. 2018-7009405 (MULTIVALENT PROBE WITH SINGLE NUCLEOTIDE RESOLUTION) was abandoned in 2019.

[94] JPN patent application 2017-506897 (A METHOD FOR DECONVOLUTION OF MIXED CELL POPULATIONS USING GENE EXPRESSION DATA) was abandoned in 2018.

[95] The family of HK patent no. 2016-111996 (MULTIPLEXABLE TAG-BASED REPORTER SYSTEM) was abandoned in 2020.

[96] The family of HK patent no. 2016-111038 (METHODS TO PREDICT RISK OF RECURRENCE IN NODE-POSITIVE EARLY BREAST CANCER) was abandoned in 2018.

[97] JPN patent application no. 2018-72708 (MULTIVARIATE DIAGNOSTIC ASSAYS AND METHODS FOR USING THE SAME) was abandoned in 2018.

[98] JPN patent application no. 2020-118680 (METHODS AND APPARATUSES FOR GENE PURIFICATION AND IMAGING) was abandoned.

METHODS AND APPARATUSES FOR GENE PURIFICATION AND IMAGING	2022-125527[99]	8/5/2022			Japan	NanoString Technologies, Inc.
PROTEIN DETECTION VIA NANOREPORTERS.	2018-105349[100]	4/24/2018			Hong Kong	NanoString Technologies, Inc.
PROTEIN DETECTION VIA NANOREPORTERS.	2016-81762[101]	4/15/2016			Japan	NanoString Technologies, Inc.
STABLE NANOREPORTERS	2016-236684[102]	20161206			Japan	NanoString Technologies, Inc.

[99] JPN patent application no. 2022-125527 (METHODS AND APPARATUSES FOR GENE PURIFICATION AND IMAGING) was abandoned.

[100] HK patent application no. 2018-105349 (PROTEIN DETECTION VIA NANOREPORTERS) was abandoned.

[101] JPN patent application no. 2016-81762 (PROTEIN DETECTION VIA NANOREPORTERS) was abandoned.

[102] JPN patent application no. 2016-236684 (STABLE NANOREPORTERS) was abandoned.